ppharmПедиатрическая фармакологияPediatric pharmacology1727-57762500-3089Издательство «ПедиатрЪ»10.15690/pf.v22i4.2938ppharm-2676Research ArticleКЛИНИЧЕСКИЕ РЕКОМЕНДАЦИИCLINICAL RECOMMENDATIONSСовременные рекомендации по ведению пациентов с бронхиальной астмойAsthma Management Current Guidelineshttps://orcid.org/0000-0002-5999-2150АвдеевC. Н.AvdeevSergey N.

Москва 

Moscow

АйсановЗ. Р.AysanovZaurbek R.

Москва

Moscow

https://orcid.org/0000-0002-5671-3478АрхиповВ. В.ArkhipovVladimir V.

Москва

Moscow

https://orcid.org/0000-0002-7691-4584АстафьеваН. Г.AstaphievaNataliya G.

Саратов

Saratov

https://orcid.org/0000-0003-3987-8112БарановА. А.BaranovAleksander A.

Москва

Moscow

https://orcid.org/0000-0001-6050-724XБелевскийА. С.BelevskiyAndrey S.

Москва

Moscow

https://orcid.org/0000-0002-8317-2718БухтияровИ. В.BukhtiyarovIgor V.

Москва

Moscow

ВасильеваО. С.VasilyevaOlga S.

 

Москва

Moscow

https://orcid.org/0000-0001-7398-0562ВишневаЕ. А.VishnevaElena A.

Москва

Moscow

https://orcid.org/0000-0003-0547-3686ГеппеН. А.GeppeNataliya A.

Москва

Moscow

https://orcid.org/0000-0001-8982-5292ДемкоИ. В.DemkoIrina V.

Красноярск

Krasnoyarsk

https://orcid.org/0000-0002-8574-6869ЕмельяновА. В.Emel’yanovAleksander V.

Санкт-Петербург

Saint Petersburg

https://orcid.org/0000-0002-0877-6554ИгнатоваГ. Л.IgnatovaGalina L.

Челябинск

Chelyabinsk

https://orcid.org/0000-0002-3556-969XИльинаН. И.Il’inaNataliya I.

Москва

Moscow

КняжескаяН. П.KnyazheskayaNadezhda P.

 

Москва

Moscow

https://orcid.org/0000-0003-3250-0694КурбачеваО. М.KurbachevaOksana M.

Москва

Moscow

https://orcid.org/0000-0002-2460-7718ЛевинаЮ. Г.LevinaYulia G.

Москва

Moscow

https://orcid.org/0000-0002-1620-7159ЛещенкоИ. В.LeshchenkoIgor V.

Екатеринбург

Yekaterinburg 

https://orcid.org/0000-0002-2686-8284МалаховА. Б.MalakhovAleksander B.

Москва

Moscow

МещеряковаН. Н.MeshcheryakovaNataliya N.

 

Москва

Moscow

https://orcid.org/0000-0002-2209-7531Намазова-БарановаЛ. С.Namazova-BaranovaLeyla S.

Москва

Moscow

https://orcid.org/0000-0002-3162-2510НенашеваН. М.NenashevaNataliya M.

Москва

Moscow

https://orcid.org/0000-0002-7571-5460НовикГ. А.NovikGennadiy A.

Санкт-Петербург

Saint Petersburg

https://orcid.org/0000-0002-4164-4094ПавловаК. С.PavlovaKseniya S.

Москва

Moscow

https://orcid.org/0000-0001-5039-8473ПампураА. Н.PampuraAleksander N.

Москва

Moscow

https://orcid.org/0000-0002-3678-7939СелимзяноваЛ. Р.SelimzyanovaLiliya R.

Селимзянова Лилия Робертовна, кандидат медицинских наук, заведующая отделом стандартизации и изучения основ доказательной медицины НИИ педиатрии и охраны здоровья детей; врач-пульмонолог 

119333, Москва, ул. Фотиевой, д. 10, тел.: +7 (499) 400-47-33 

Moscow

lilysir@mail.ruhttps://orcid.org/0000-0002-2291-6453СтрижаковЛ. А.StrizhakovLeonid A.

Москва

Moscow

https://orcid.org/0000-0002-5083-6637ФоминаД. С.FominaDariya S.

Москва

Moscow

https://orcid.org/0000-0002-2397-5172ХаитовМ. Р.HaitovMusa R.

Москва

Moscow

https://orcid.org/0000-0002-6808-5528ЧучалинА. Г.ChuchalinAleksander G.

Москва

Moscow

https://orcid.org/0000-0001-6098-7028ШишиморовИ. Н.ShishimorovIvan N.

Волгоград

Volgograd

https://orcid.org/0000-0003-0871-7551ШпагинаЛ. А.ShpaginaLubov A.

Новосибирск

Novosibirsk

https://orcid.org/0000-0003-0317-2425ЭфендиеваК. Е.EfendievaKamilla E.

Москва

Moscow

Научно-исследовательский институт пульмонологии ; Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)РоссияResearch Institute of Pulmonology ; Sechenov First Moscow State Medical UniversityRussian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет)РоссияPirogov Russian National Research Medical UniversityRussian FederationРоссийская медицинская академия непрерывного профессионального образованияРоссияRussian Medical Academy of Continuing Professional EducationRussian FederationСаратовский государственный медицинский университет им. В.И. РазумовскогоРоссияRazumovskiy Saratov State Medical UniversityRussian FederationПервый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет) ; НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»РоссияSechenov First Moscow State Medical University ; Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryRussian FederationНаучно-исследовательский институт медицины труда им. акад. Н.Ф. ИзмероваРоссияIzmerov Research Institute of Occupational HealthRussian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет) ; НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»РоссияPirogov Russian National Research Medical University ; Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryRussian FederationПервый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет)РоссияSechenov First Moscow State Medical UniversityRussian FederationКрасноярский государственный медицинский университет им. проф. В.Ф. Войно-ЯсенецкогоРоссияV.F. Voyno-Yasenetsky Krasnoyarsk State Medical UniversityRussian FederationСеверо-Западный государственный медицинский университет им. И.И. МечниковаРоссияI.I. Mechnikov North-Western State Medical UniversityRussian FederationЮжно-Уральский государственный медицинский университетРоссияSouth Ural State Medical UniversityRussian FederationГосударственный научный центр «Институт иммунологии»РоссияGovernment Research Centre “Institute of Immunology”Russian FederationГосударственный научный центр «Институт иммунологии» ; Московский государственный медико-стоматологический университет им. А.И. ЕвдокимоваРоссияGovernment Research Centre “Institute of Immunology” ; A.I. Evdokimov Moscow State University of Medicine and DentistryRussian FederationУральский государственный медицинский университетРоссияUral State Medical UniversityRussian FederationНаучно-исследовательский институт пульмонологииРоссияResearch Institute of PulmonologyRussian FederationСанкт-Петербургский государственный педиатрический медицинский университетРоссияSaint Petersburg State Pediatric Medical UniversityRussian FederationПервый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет) ; Российский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет) ; НИИ педиатрии и охраны здоровья детей НКЦ №2 ФГБНУ «РНЦХ им. акад. Б.В. Петровского»РоссияSechenov First Moscow State Medical University ; Pirogov Russian National Research Medical University ; Research Institute of Pediatrics and Children’s Health in Petrovsky National Research Centre of SurgeryRussian FederationПервый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский Университет) ; Городская клиническая больница № 52РоссияSechenov First Moscow State Medical University ; City Clinical Hospital No. 52Russian FederationРоссийский национальный исследовательский медицинский университет им. Н.И. Пирогова (Пироговский Университет) ; Государственный научный центр «Институт иммунологии»РоссияPirogov Russian National Research Medical University ; Government Research Centre “Institute of Immunology”Russian FederationВолгоградский государственный медицинский университетРоссияVolgograd State Medical UniversityRussian FederationНовосибирский государственный медицинский университетРоссияNovosibirsk State Medical UniversityRussian Federation202506102025224432494Copyright © Авдеев C.Н., Айсанов З.Р., Архипов В.В., Астафьева Н.Г., Баранов А.А., Белевский А.С., Бухтияров И.В., Васильева О.С., Вишнева Е.А., Геппе Н.А., Демко И.В., Емельянов А.В., Игнатова Г.Л., Ильина Н.И., Княжеская Н.П., Курбачева О.М., Левина Ю.Г., Лещенко И.В., Малахов А.Б., Мещерякова Н.Н., Намазова-Баранова Л.С., Ненашева Н.М., Новик Г.А., Павлова К.С., Пампура А.Н., Селимзянова Л.Р., Стрижаков Л.А., Фомина Д.С., Хаитов М.Р., Чучалин А.Г., Шишиморов И.Н., Шпагина Л.А., Эфендиева К.Е., 20252025Авдеев C.Н., Айсанов З.Р., Архипов В.В., Астафьева Н.Г., Баранов А.А., Белевский А.С., Бухтияров И.В., Васильева О.С., Вишнева Е.А., Геппе Н.А., Демко И.В., Емельянов А.В., Игнатова Г.Л., Ильина Н.И., Княжеская Н.П., Курбачева О.М., Левина Ю.Г., Лещенко И.В., Малахов А.Б., Мещерякова Н.Н., Намазова-Баранова Л.С., Ненашева Н.М., Новик Г.А., Павлова К.С., Пампура А.Н., Селимзянова Л.Р., Стрижаков Л.А., Фомина Д.С., Хаитов М.Р., Чучалин А.Г., Шишиморов И.Н., Шпагина Л.А., Эфендиева К.Е.Avdeev S.N., Aysanov Z.R., Arkhipov V.V., Astaphieva N.G., Baranov A.A., Belevskiy A.S., Bukhtiyarov I.V., Vasilyeva O.S., Vishneva E.A., Geppe N.A., Demko I.V., Emel’yanov A.V., Ignatova G.L., Il’ina N.I., Knyazheskaya N.P., Kurbacheva O.M., Levina Y.G., Leshchenko I.V., Malakhov A.B., Meshcheryakova N.N., Namazova-Baranova L.S., Nenasheva N.M., Novik G.A., Pavlova K.S., Pampura A.N., Selimzyanova L.R., Strizhakov L.A., Fomina D.S., Haitov M.R., Chuchalin A.G., Shishimorov I.N., Shpagina L.A., Efendieva K.E.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pedpharma.ru/jour/article/view/2676

Клинические рекомендации по бронхиальной астме представляют собой изложение систематизированного подхода к диагностике и лечению этого хронического воспалительного заболевания дыхательных путей для достижения контроля над ним. В статье подробно описаны современные методы диагностики, включая анамнез, физикальное обследование, функциональные пробы легких и определение уровня воспаления. Особое внимание уделяется индивидуализации терапии с учетом степени тяжести и контроля над заболеванием, а также наличия сопутствующих состояний. Авторами подчеркивается важность использования ингаляционных глюкокортикоидов как основы долгосрочного контроля и назначения бронхолитиков быстрого действия для симптоматического облегчения. Также рассматриваются нефармакологические меры: избегание контакта с аллергенами, изменение образа жизни, обучение пациентов правильному использованию ингаляторов и самостоятельному контролю за симптомами. Важной частью являются стратегия «поддерживающей терапии» и план действий при обострениях, что способствует своевременному реагированию и снижению риска тяжелых состояний. Авторы подчеркивают необходимость регулярного мониторинга эффективности лечения и коррекции терапии в зависимости от динамики заболевания. Данные клинические рекомендации направлены на повышение качества медицинской помощи пациентам с бронхиальной астмой, снижение частоты обострений болезни и улучшение качества жизни больных за счет внедрения современных доказательных методов диагностики и терапии.

The clinical guidelines for asthma provide a systematic approach to the diagnosis and treatment of this chronic inflammatory disease of the respiratory tract. The article provides a detailed description of current diagnostic methods, including history taking, physical examination, pulmonary function tests, and inflammation measurements. The focus is on individualizing therapy based on the severity and control of the disease, as well as the presence of comorbidities. The authors emphasize the importance of using inhaled corticosteroids as the foundation for long-term control and the use of fast-acting bronchodilators for symptomatic relief. The guidelines also cover non-pharmacological measures, such as avoiding allergens, lifestyle changes, and teaching patients how to properly use inhalers and monitor their symptoms. An important aspect of the guidelines is the “supportive therapy” strategy and the plan of action for exacerbations, which helps to respond promptly and reduce the risk of severe conditions. The guidelines emphasize the need for regular monitoring of treatment effectiveness and the adjustment of therapy based on the progression of the disease. The goal of these clinical guidelines is to improve the quality of care for patients with asthma, reduce the frequency of exacerbations, and enhance their quality of life through the implementation of evidencebased diagnostic and treatment methods.

детибронхиальная астмаклинические рекомендациитерапиядиагностикаchildrenasthmaclinical guidelinesmanagementdiagnosticsНе указано.Not specified.ReferencesRay A, Camiolo M, Fitzpatrick A, et al. Are We Meeting the Promise of Endotypes and Precision Medicine in Asthma? Physiol Rev. 2020;100(3):983–1017. doi: https://doi.org/10.1152/PHYSREV.00023.2019Ray A, Camiolo M, Fitzpatrick A, et al. Are We Meeting the Promise of Endotypes and Precision Medicine in Asthma? Physiol Rev. 2020;100(3):983–1017. doi: https://doi.org/10.1152/PHYSREV.00023.2019Moore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–323. doi: https://doi.org/10.1164/RCCM.200906-0896OCMoore WC, Meyers DA, Wenzel SE, et al. Identification of asthma phenotypes using cluster analysis in the Severe Asthma Research Program. Am J Respir Crit Care Med. 2010;181(4):315–323. doi: https://doi.org/10.1164/RCCM.200906-0896OCAbbafati C, Abbas KM, Abbasi M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi: https://doi.org/10.1016/S0140-6736(20)30925-9Abbafati C, Abbas KM, Abbasi M, et al. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1204–1222. doi: https://doi.org/10.1016/S0140-6736(20)30925-9Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA); 2020. 209 p. Available online: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-fullreport_-final-_wms.pdf. Accessed on June 26, 2025.Global strategy for asthma management and prevention. Global Initiative for Asthma (GINA); 2020. 209 p. Available online: https://ginasthma.org/wp-content/uploads/2020/04/GINA-2020-fullreport_-final-_wms.pdf. Accessed on June 26, 2025.Chuchalin AG, Khaltaev N, Antonov NS, et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9:963–974. doi: https://doi.org/10.2147/COPD.S67283Chuchalin AG, Khaltaev N, Antonov NS, et al. Chronic respiratory diseases and risk factors in 12 regions of the Russian Federation. Int J Chron Obstruct Pulmon Dis. 2014;9:963–974. doi: https://doi.org/10.2147/COPD.S67283Национальная программа «Бронхиальная астма у детей. Стратегия лечения и профилактика». — 4-е изд. — М.; 2012. — 182 с.Natsional’naya programma “Bronkhial’naya astma u detei. Strategiya lecheniya i profilaktika”. 4th edn. Moscow; 2012. 182 p. (In Russ).Most Recent Asthma Data. In: CDC. U.S. Centers for Disease Control and Prevention: Official Website. Retrieved February 9, 2024. Available online: https://www.cdc.gov/asthma/most_recent_data.htm. Accessed on June 18, 2025.Most Recent Asthma Data. In: CDC. U.S. Centers for Disease Control and Prevention: Official Website. Retrieved February 9, 2024. Available online: https://www.cdc.gov/asthma/most_recent_data.htm. Accessed on June 18, 2025.Медицинская статистика // ФГБУ «ЦНИИОИЗ» Минздрава России: Официальный сайт. Доступно по: https://mednet.ru/napravleniya/mediczinskaya-statistika. Ссылка активна на 18.06.2025.Medical statistics. In: RIH. Russian research Institute of Health: Official Website. (In Russ). Доступно по: https://mednet.ru/napravleniya/mediczinskaya-statistika. Ссылка активна на 18.06.2025.Krahn M, Berka C, Langlois P, Detsky AS. Direct and indirect costs of asthma in Canada, 1990. CMAJ. 1996;154(6):821–831.Krahn M, Berka C, Langlois P, Detsky AS. Direct and indirect costs of asthma in Canada, 1990. CMAJ. 1996;154(6):821–831.Braman SS, Kaemmerlen JT. Intensive Care of Status Asthmaticus: A 10-Year Experience. JAMA. 1990;264(3):366–368. doi: https://doi.org/10.1001/JAMA.1990.03450030090038Braman SS, Kaemmerlen JT. Intensive Care of Status Asthmaticus: A 10-Year Experience. JAMA. 1990;264(3):366–368. doi: https://doi.org/10.1001/JAMA.1990.03450030090038Weber EJ, Silverman RA, Callaham ML, et al. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. Am J Med. 2002;113(5): 371–378. doi: https://doi.org/10.1016/S0002-9343(02)01242-1Weber EJ, Silverman RA, Callaham ML, et al. A prospective multicenter study of factors associated with hospital admission among adults with acute asthma. Am J Med. 2002;113(5): 371–378. doi: https://doi.org/10.1016/S0002-9343(02)01242-1Salmeron S, Liard R, Elkharrat D, et al. Asthma severity and adequacy of management in accident and emergency departments in France: A prospective study. Lancet. 2001;358(9282):629–635. doi: https://doi.org/10.1016/S0140-6736(01)05779-8Salmeron S, Liard R, Elkharrat D, et al. Asthma severity and adequacy of management in accident and emergency departments in France: A prospective study. Lancet. 2001;358(9282):629–635. doi: https://doi.org/10.1016/S0140-6736(01)05779-8Krishnan V, Diette GB, Rand CS, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med. 2006;174(6):633–638. doi: https://doi.org/10.1164/RCCM.200601-007OCKrishnan V, Diette GB, Rand CS, et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med. 2006;174(6):633–638. doi: https://doi.org/10.1164/RCCM.200601-007OCНенашева Н.М. Клинические фенотипы атопической бронхиальной астмы: диагностика и лечение. — Palmarium Academic Publishing; 2012. — 319 с.Nenasheva NM. Klinicheskie fenotipy atopicheskoi bronkhial’noi astmy: diagnostika i lechenie. Palmarium Academic Publishing; 2012. 319 p. (In Russ).Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax. 1999;54(3):268–272. doi: https://doi.org/10.1136/THX.54.3.268Pearce N, Pekkanen J, Beasley R. How much asthma is really attributable to atopy? Thorax. 1999;54(3):268–272. doi: https://doi.org/10.1136/THX.54.3.268Reddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1): 59–99. doi: https://doi.org/10.1164/RCCM.200801-060STReddel HK, Taylor DR, Bateman ED, et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med. 2009;180(1): 59–99. doi: https://doi.org/10.1164/RCCM.200801-060STTaylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008;32(3): 545–554. doi: https://doi.org/10.1183/09031936.00155307Taylor DR, Bateman ED, Boulet LP, et al. A new perspective on concepts of asthma severity and control. Eur Respir J. 2008;32(3): 545–554. doi: https://doi.org/10.1183/09031936.00155307Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi: https://doi.org/10.1183/09031936.00202013Chung KF, Wenzel SE, Brozek JL, et al. International ERS/ ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43(2):343–373. doi: https://doi.org/10.1183/09031936.00202013Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA); 2024. 261 p. Available online: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. Accessed on June 19, 2024.Global Strategy for Asthma Management and Prevention. Global Initiative for Asthma (GINA); 2024. 261 p. Available online: https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf. Accessed on June 19, 2024.Barnes PJ, Szefler SJ, Reddel HK, Chipps BE. Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. J Allergy Clin Immunol. 2029;144(5):1180–1186. doi: https://doi.org/10.1016/J.JACI.2019.06.040Barnes PJ, Szefler SJ, Reddel HK, Chipps BE. Symptoms and perception of airway obstruction in asthmatic patients: Clinical implications for use of reliever medications. J Allergy Clin Immunol. 2029;144(5):1180–1186. doi: https://doi.org/10.1016/J.JACI.2019.06.040Killian KJ, Watson R, Otis J, et al. Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med. 2000;162(2 Pt 1):490–496. doi: https://doi.org/10.1164/AJRCCM.162.2.9905079Killian KJ, Watson R, Otis J, et al. Symptom perception during acute bronchoconstriction. Am J Respir Crit Care Med. 2000;162(2 Pt 1):490–496. doi: https://doi.org/10.1164/AJRCCM.162.2.9905079Авдеев С.Н. Дыхательная недостаточность // Атмосфера. Пульмонология и аллергология. — 2004. — № 1. — С. 21–27.Avdeev SN. Dykhatel’naya nedostatochnost’. Atmosfera. Pul’monologiya i allergologiya. 2004;(1):21–27. (In Russ).Горячкина Л.А., Ненашева Н.М., Тотикова М.Ч., Шмелева Н.В. Особенности бронхиальной астмы у подростков мужского пола // Пульмонология. — 2008. — № 2. — С. 15–19. — doi: https://doi.org/10.18093/0869-0189-2008-0-2-15-19Goryachkina LA, Nenasheva NM, Totikova MCh, Shmeleva NV. Features of bronchial asthma in male adolescents. Pulmonologiya. 2008;(2):15–19. (In Russ). doi: https://doi.org/10.18093/0869-0189-2008-0-2-15-19Шальнова О.А., Кириллов М.М., Орлова М.М. и др. Изучение патологии легких у юношей призывного возраста как возможность исследования ранних форм бронхиальной астмы и хронического бронхита // Пульмонология. — 2005. — № 2. — С. 57–62. — doi: https://doi.org/10.18093/0869-0189-2005-0-2-57-62Shalnova OA, Kirillov MM, Orlova MM, et al. Lung diseases in called-up aged patients. Pulmonologiya. 2005;(2):57–62. (In Russ). doi: https://doi.org/10.18093/0869-0189-2005-0-2-57-62Жолондзь Н.Н., Воронина Н.В., Мамровская Т.П. и др. Особенности течения бронхиальной астмы у подростков и юношей призывного возраста // Дальневосточный медицинский журнал. — 2011. — № 3. — С. 57–59.Zholonds NN, Voronina NV, Mamrovska TP, et al. Bronchial asthma in teenagers and youths of call-up age. Far Eastern Medical Journal. 2011;(3):57–59. (In Russ).Астафьева Н.Г. Бронхиальная астма у подростков // Аллергология. — 2005. — № 2. — С. 41–49.Astafieva NG. Bronchial asthma in adolescents. Allergology. 2005;(2):41–49. (In Russ).Емельянов А.В. Особенности бронхиальной астмы в пожилом и старческом возрасте // РМЖ. — 2016. — № 16. — С. 1102–1107. — doi: https://doi.org/10.18565/PHARMATECA.2020.5.85-94Emelyanov AV. Features of asthma in elderly patients. RMJ. 2016;(16):1102–1107. (In Russ). doi: https://doi.org/10.18565/PHARMATECA.2020.5.85-94Mellis C. Respiratory noises: how useful are they clinically? Pediatr Clin North Am. 2029;56(1):1–17. doi: https://doi.org/10.1016/J.PCL.2008.10.003Mellis C. Respiratory noises: how useful are they clinically? Pediatr Clin North Am. 2029;56(1):1–17. doi: https://doi.org/10.1016/J.PCL.2008.10.003Louis R, Satia I, Ojanguren I, et al. European Respiratory Society Guidelines for the Diagnosis of Asthma in Adults. Eur Respir J. 2022;60(3):2101585. doi: https://doi.org/10.1183/13993003.01585-2021Louis R, Satia I, Ojanguren I, et al. European Respiratory Society Guidelines for the Diagnosis of Asthma in Adults. Eur Respir J. 2022;60(3):2101585. doi: https://doi.org/10.1183/13993003.01585-2021Sung L, Osmond MH, Klassen TP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med. 1998;5(3):209–213. doi: https://doi.org/10.1111/J.1553-2712.1998.TB02614.XSung L, Osmond MH, Klassen TP. Randomized, controlled trial of inhaled budesonide as an adjunct to oral prednisone in acute asthma. Acad Emerg Med. 1998;5(3):209–213. doi: https://doi.org/10.1111/J.1553-2712.1998.TB02614.XPollart SM, Compton RM, Elward KS. Management of Acute Asthma Exacerbations. Am Fam Physician. 2011;84(1):40–47. doi: https://www.aafp.org/pubs/afp/issues/2011/0701/p40.htmlPollart SM, Compton RM, Elward KS. Management of Acute Asthma Exacerbations. Am Fam Physician. 2011;84(1):40–47. doi: https://www.aafp.org/pubs/afp/issues/2011/0701/p40.htmlВолчков В.А., Титова О.Н., Черный О.М. Клинические рекомендации (протокол) по оказанию скорой медицинской помощи при острой дыхательной недостаточности // Скорая медицинская помощь. Клинические рекомендации / под ред. С.Ф. Багненко. — М.: ГЭОТАР-Медиа; 2022. — С. 132–149.Volchkov VA, Titova ON, Chernyi OM. Klinicheskie rekomendatsii (protokol) po okazaniyu skoroi meditsinskoi pomoshchi pri ostroi dykhatel’noi nedostatochnosti. In: Skoraya meditsinskaya pomoshch’. Klinicheskie rekomendatsii. Bagnenko SF, ed. Moscow: GEOTAR-Media; 2022. pp. 132–149. (In Russ).]Вишнёва Е.А., Намазова-Баранова Л.С., Алексеева А.А. и др. Актуальная тактика ведения детей с бронхиальной астмой // Педиатрическая фармакология. — 2017. — Т. 14. — № 6. — С. 443–458. — doi: https://doi.org/10.15690/pf.v14i6.1828Vishneva EA, Namazova-Baranova LS, Alekseeva AA, et al. Actual Surveillance of Children with Bronchial Asthma. Pediatricheskaya farmakologiya — Pediatric pharmacology. 2017;14(6):443–458. (In Russ). doi: https://doi.org/10.15690/pf.v14i6.1828Thomas M, Kay S, Pike J, et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J. 2009; 18(1):41–49. doi: https://doi.org/10.4104/PCRJ.2009.00010Thomas M, Kay S, Pike J, et al. The Asthma Control Test (ACT) as a predictor of GINA guideline-defined asthma control: analysis of a multinational cross-sectional survey. Prim Care Respir J. 2009; 18(1):41–49. doi: https://doi.org/10.4104/PCRJ.2009.00010Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med. 2007;101(12):2437–2446. doi: https://doi.org/10.1016/J.RMED.2007.07.014Bousquet J, Boulet LP, Peters MJ, et al. Budesonide/formoterol for maintenance and relief in uncontrolled asthma vs. high-dose salmeterol/fluticasone. Respir Med. 2007;101(12):2437–2446. doi: https://doi.org/10.1016/J.RMED.2007.07.014Buhl R, Kuna P, Peters MJ, et al. The effect of budesonide/ formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res. 2012;13(1):59. doi: https://doi.org/10.1186/1465-9921-13-59Buhl R, Kuna P, Peters MJ, et al. The effect of budesonide/ formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever use: an exploratory analysis of two randomised, controlled studies with comparisons to standard therapy. Respir Res. 2012;13(1):59. doi: https://doi.org/10.1186/1465-9921-13-59Albers FC, Licskai C, Chanez P, et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019;159:105806. doi: https://doi.org/10.1016/J.RMED.2019.105806Albers FC, Licskai C, Chanez P, et al. Baseline blood eosinophil count as a predictor of treatment response to the licensed dose of mepolizumab in severe eosinophilic asthma. Respir Med. 2019;159:105806. doi: https://doi.org/10.1016/J.RMED.2019.105806Bush A. Management of asthma in children. Minerva Pediatr. 2018;70(5):444–457. doi: https://doi.org/10.23736/S0026-4946.18.05351-3Bush A. Management of asthma in children. Minerva Pediatr. 2018;70(5):444–457. doi: https://doi.org/10.23736/S0026-4946.18.05351-3Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849–858. doi: https://doi.org/10.1016/S2213-2600(15)00367-7Price DB, Rigazio A, Campbell JD, et al. Blood eosinophil count and prospective annual asthma disease burden: a UK cohort study. Lancet Respir Med. 2015;3(11):849–858. doi: https://doi.org/10.1016/S2213-2600(15)00367-7Kerkhof M, Tran TN, van den Berge M, et al. Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. PloS One. 2018;13(7):e0201143. doi: https://doi.org/10.1371/JOURNAL.PONE.0201143Kerkhof M, Tran TN, van den Berge M, et al. Association between blood eosinophil count and risk of readmission for patients with asthma: Historical cohort study. PloS One. 2018;13(7):e0201143. doi: https://doi.org/10.1371/JOURNAL.PONE.0201143Xepapadaki P, Adachi Y, Pozo Beltrán CF, et al. Utility of biomarkers in the diagnosis and monitoring of asthmatic children. World Allergy Organ J. 2022;16(1):100727. doi: https://doi.org/10.1016/J.WAOJOU.2022.100727Xepapadaki P, Adachi Y, Pozo Beltrán CF, et al. Utility of biomarkers in the diagnosis and monitoring of asthmatic children. World Allergy Organ J. 2022;16(1):100727. doi: https://doi.org/10.1016/J.WAOJOU.2022.100727Bonato M, Bazzan E, Snijders D, et al. Blood eosinophils relate to atopy and not to tissue eosinophils in wheezing children. Allergy. 2020;75(6):1497–1501. doi: https://doi.org/10.1111/ALL.14170Bonato M, Bazzan E, Snijders D, et al. Blood eosinophils relate to atopy and not to tissue eosinophils in wheezing children. Allergy. 2020;75(6):1497–1501. doi: https://doi.org/10.1111/ALL.14170Diagnosis and Management of Difficult-to-treat and Severe Asthma in Adolescent and adult patients. Global Initiative for Asthma (GINA); 2024. 35 p. Available online: https://ginasthma.org/wp-content/uploads/2024/11/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf. Accessed on June 20, 2024.Diagnosis and Management of Difficult-to-treat and Severe Asthma in Adolescent and adult patients. Global Initiative for Asthma (GINA); 2024. 35 p. Available online: https://ginasthma.org/wp-content/uploads/2024/11/GINA-Severe-Asthma-Guide-2024-WEB-WMS.pdf. Accessed on June 20, 2024.Smith AD, Cowan JO, Filsell S, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Criti Care Med. 2004;169(4): 473–478. doi: https://doi.org/10.1164/RCCM.200310-1376OCSmith AD, Cowan JO, Filsell S, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Criti Care Med. 2004;169(4): 473–478. doi: https://doi.org/10.1164/RCCM.200310-1376OCFabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(3):418–424. doi: https://doi.org/10.1164/RCCM.200203-183OCFabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2003;167(3):418–424. doi: https://doi.org/10.1164/RCCM.200203-183OCKorevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(4):290–300. doi: https://doi.org/10.1016/S2213-2600(15)00050-8Korevaar DA, Westerhof GA, Wang J, et al. Diagnostic accuracy of minimally invasive markers for detection of airway eosinophilia in asthma: a systematic review and meta-analysis. Lancet Respir Med. 2015;3(4):290–300. doi: https://doi.org/10.1016/S2213-2600(15)00050-8Barcellos VA, dos Santos VCH, Moreira MÂF, Dalcin PTR. Asthma control and sputum eosinophils in adult patients: a cross-sectional study in southern Brazil. Sci Rep. 2023;13(1):21464. doi: https://doi.org/10.1038/S41598-023-48381-1Barcellos VA, dos Santos VCH, Moreira MÂF, Dalcin PTR. Asthma control and sputum eosinophils in adult patients: a cross-sectional study in southern Brazil. Sci Rep. 2023;13(1):21464. doi: https://doi.org/10.1038/S41598-023-48381-1Talini D, Novelli F, Bacci E, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open. 2015;5(1):e005748. doi: https://doi.org/10.1136/BMJOPEN-2014-005748Talini D, Novelli F, Bacci E, et al. Sputum eosinophilia is a determinant of FEV1 decline in occupational asthma: results of an observational study. BMJ Open. 2015;5(1):e005748. doi: https://doi.org/10.1136/BMJOPEN-2014-005748Parameswaran K, Leigh R, Hargreave FE. Sputum eosinophil count to assess compliance with corticosteroid therapy in asthma. J Allergy Clin Immunol. 1999;104(2 Pt 1): 502–503. doi: https://doi.org/10.1016/S0091-6749(99)70402-1Parameswaran K, Leigh R, Hargreave FE. Sputum eosinophil count to assess compliance with corticosteroid therapy in asthma. J Allergy Clin Immunol. 1999;104(2 Pt 1): 502–503. doi: https://doi.org/10.1016/S0091-6749(99)70402-1Atkinson CE, Schworer SA, Matthews K, et al. Omalizumab is associated with improved asthma outcomes in children and adolescents with serum immunoglobulin E above dosing guidelines. J Allergy Clin Immunol Pract. 2022;10(10):2756–2757.e1. doi: https://doi.org/10.1016/J.JAIP.2022.06.041Atkinson CE, Schworer SA, Matthews K, et al. Omalizumab is associated with improved asthma outcomes in children and adolescents with serum immunoglobulin E above dosing guidelines. J Allergy Clin Immunol Pract. 2022;10(10):2756–2757.e1. doi: https://doi.org/10.1016/J.JAIP.2022.06.041Hew M, Gillman A, Sutherland M, et al. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. Clin Exp Allergy. 2016;46(11):1407–1415. doi: https://doi.org/10.1111/CEA.12774Hew M, Gillman A, Sutherland M, et al. Real-life effectiveness of omalizumab in severe allergic asthma above the recommended dosing range criteria. Clin Exp Allergy. 2016;46(11):1407–1415. doi: https://doi.org/10.1111/CEA.12774Аллергология и иммунология: национальное руководство / под ред. Р.М. Хаитова, Н.И. Ильиной. — М.: ГЭОТАР-Медиа; 2009. — 656 с.Allergologiya i immunologiya: National guide. Khaitov RM, Il’ina NI, et al. Moscow: GEOTAR-Media; 2009. 656 p. (In Russ).Cox L. Overview of serological-specific IgE antibody testing in children. Curr Allergy Asthma Rep. 2011;11(6):447–453. doi: https://doi.org/10.1007/S11882-011-0226-3Cox L. Overview of serological-specific IgE antibody testing in children. Curr Allergy Asthma Rep. 2011;11(6):447–453. doi: https://doi.org/10.1007/S11882-011-0226-3Ansotegui IJ, Melioli G, Canonica GW, et al. A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. World Allergy Organ J. 2020;13(2):100091. doi: https://doi.org/10.1016/J.WAOJOU.2019.100091Ansotegui IJ, Melioli G, Canonica GW, et al. A WAO — ARIA — GA2LEN consensus document on molecular-based allergy diagnosis (PAMD@): Update 2020. World Allergy Organ J. 2020;13(2):100091. doi: https://doi.org/10.1016/J.WAOJOU.2019.100091Azad MB, Chan-Yeung M, Chan ES, et al. Wheezing Patterns in Early Childhood and the Risk of Respiratory and Allergic Disease in Adolescence. JAMA Pediatr. 2016;170(4):393–395. doi: https://doi.org/10.1001/JAMAPEDIATRICS.2015.4127Azad MB, Chan-Yeung M, Chan ES, et al. Wheezing Patterns in Early Childhood and the Risk of Respiratory and Allergic Disease in Adolescence. JAMA Pediatr. 2016;170(4):393–395. doi: https://doi.org/10.1001/JAMAPEDIATRICS.2015.4127Nowak RM, Tomlanovich MC, Sarkar DD, et al. Arterial blood gases and pulmonary function testing in acute bronchial asthma. Predicting patient outcomes. JAMA. 1983;249(15):2043–2046.Nowak RM, Tomlanovich MC, Sarkar DD, et al. Arterial blood gases and pulmonary function testing in acute bronchial asthma. Predicting patient outcomes. JAMA. 1983;249(15):2043–2046.Первичные иммунодефициты с преимущественной недостаточностью синтеза антител: клинические рекомендации / Российская ассоциация аллергологов и клинических иммунологов; Национальная Ассоциация Экспертов в области Первичных Иммунодефицитов. — Минздрав России; 2024. — 69 с. Доступно по: https://cr.minzdrav.gov.ru/schema/view-cr/735_1. Ссылка активна на 21.06.2025.Pervichnye immunodefitsity s preimushchestvennoi nedostatochnost’yu sinteza antitel: Clinical guidelines. Russian Association of Allergists and Clinical Immunologists; National Association of Experts in Primary Immunodeficiencies. Ministry of Health of the Russian Federation; 2024. 69 p. (In Russ).]Доступно по: https://cr.minzdrav.gov.ru/schema/view-cr/735_1. Ссылка активна на 21.06.2025.Чучалин А.Г. Болезни, ассоциированные с иммуноглобулином G // Терапевтический архив. — 2018. — Т. 90. — № 3. — C. 4–9. — doi: https://doi.org/10.26442/terarkh20189034-9Chuchalin AG. Disease associated with immunoglobulin G. Terapevticheskii arkhiv. 2018;90(3):4–9. (In Russ). doi: https://doi.org/10.26442/terarkh20189034-9Латышева Т.В., Медуницына Е.Н. Инфекционные заболевания дыхательного тракта у больных с бронхиальной астмой // РМЖ. — 2007. — № 7. — С. 60.Latysheva TV, Medunitsyna EN. Infektsionnye zabolevaniya dykhatel’nogo trakta u bol’nykh s bronkhial’noi astmoi. RMJ. 2007;(7):60. (In Russ).Liu XX, Zhu XM, Miao Q, et al. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324–332. doi: https://doi.org/10.1159/000365892Liu XX, Zhu XM, Miao Q, et al. Hyperglycemia induced by glucocorticoids in nondiabetic patients: a meta-analysis. Ann Nutr Metab. 2014;65(4):324–332. doi: https://doi.org/10.1159/000365892Seelig E, Meyer S, Timper K, et al. Metformin prevents metabolic side effects during systemic glucocorticoid treatment. Eur J Endocrinol. 2017;176(3):349–358. doi: https://doi.org/10.1530/EJE-16-0653Seelig E, Meyer S, Timper K, et al. Metformin prevents metabolic side effects during systemic glucocorticoid treatment. Eur J Endocrinol. 2017;176(3):349–358. doi: https://doi.org/10.1530/EJE-16-0653Mishra A, Ugra D, Kumar U. Study of spirometry parameters in suspected asthmatic children in a tertiary care hospital. Int J Contemp Pediatric. 2020;7(5):1023. doi: https://doi.org/10.18203/2349-3291.IJCP20201631Mishra A, Ugra D, Kumar U. Study of spirometry parameters in suspected asthmatic children in a tertiary care hospital. Int J Contemp Pediatric. 2020;7(5):1023. doi: https://doi.org/10.18203/2349-3291.IJCP20201631Gaillard EA, Kuehni CE, Turner S, et al. European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years. Eur Resp J. 2021;58(5):2004173. doi: https://doi.org/10.1183/13993003.04173-2020Gaillard EA, Kuehni CE, Turner S, et al. European Respiratory Society clinical practice guidelines for the diagnosis of asthma in children aged 5–16 years. Eur Resp J. 2021;58(5):2004173. doi: https://doi.org/10.1183/13993003.04173-2020Singh D, Garcia G, Maneechotesuwan K, et al. New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management. Adv Ther. 2022;39(5): 1895–1914. doi: https://doi.org/10.1007/s12325-022-02092-7Singh D, Garcia G, Maneechotesuwan K, et al. New Versus Old: The Impact of Changing Patterns of Inhaled Corticosteroid Prescribing and Dosing Regimens in Asthma Management. Adv Ther. 2022;39(5): 1895–1914. doi: https://doi.org/10.1007/s12325-022-02092-7Vogelmeier C, Naya I, Ekelund J. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged >16 years) with asthma: a sub-analysis of the COSMOS study. Clin Drug Investig. 2012;32(7):439–449. doi: https://doi.org/10.2165/11598840-000000000-00000Vogelmeier C, Naya I, Ekelund J. Budesonide/formoterol maintenance and reliever therapy in Asian patients (aged >16 years) with asthma: a sub-analysis of the COSMOS study. Clin Drug Investig. 2012;32(7):439–449. doi: https://doi.org/10.2165/11598840-000000000-00000Papanicolaou A, Wang H, Satzke C, et al. Novel Therapies for Pneumonia-Associated Severe Asthma Phenotypes. Trends Mol Med. 2020;26(11):1047–1058. doi: https://doi.org/10.1016/J.MOLMED.2020.07.006Papanicolaou A, Wang H, Satzke C, et al. Novel Therapies for Pneumonia-Associated Severe Asthma Phenotypes. Trends Mol Med. 2020;26(11):1047–1058. doi: https://doi.org/10.1016/J.MOLMED.2020.07.006Бекетова Т.В., Волков М.Ю. Международные рекомендации по диагностике и лечению эозинофильного гранулематоза с полиангиитом — 2015 // Научно-практическая ревматология. — 2016. — Т. 54. — № 2. — С. 129–137. — doi: https://doi.org/10.14412/1995-4484-2016-129-137Beketova TV, Volkov MYu. The 2015 International guidelines for the diagnosis and treatment of eosinophilic granulomatosis with polyangiitis. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2016;54(2):129–137. (In Russ). doi: https://doi.org/10.14412/1995-4484-2016-129-137Lanham J, Elkon K, Pusey C, Hughes G. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63(2):65–81. doi: https://doi.org/10.1097/00005792-198403000-00001Lanham J, Elkon K, Pusey C, Hughes G. Systemic vasculitis with asthma and eosinophilia: a clinical approach to the Churg-Strauss syndrome. Medicine (Baltimore). 1984;63(2):65–81. doi: https://doi.org/10.1097/00005792-198403000-00001Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607–612. doi: https://doi.org/10.1016/j.jaci.2012.02.019Valent P, Klion AD, Horny HP, et al. Contemporary consensus proposal on criteria and classification of eosinophilic disorders and related syndromes. J Allergy Clin Immunol. 2012;130(3):607–612. doi: https://doi.org/10.1016/j.jaci.2012.02.019Taylor MR, Keane CT, O’Connor P, et al. The expanded spectrum of toxocaral disease. Lancet. 1998;1(8587):692–695. doi: https://doi.org/10.1016/S0140-6736(88)91486-9Taylor MR, Keane CT, O’Connor P, et al. The expanded spectrum of toxocaral disease. Lancet. 1998;1(8587):692–695. doi: https://doi.org/10.1016/S0140-6736(88)91486-9Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis. 2001;33(7):1040–1047. doi: https://doi.org/10.1086/322707Siddiqui AA, Berk SL. Diagnosis of Strongyloides stercoralis infection. Clin Infect Dis. 2001;33(7):1040–1047. doi: https://doi.org/10.1086/322707Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009;135(3):805–826. doi: https://doi.org/10.1378/chest.08-2586Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009;135(3):805–826. doi: https://doi.org/10.1378/chest.08-2586Gotlib J. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2015;90(11):1077–1189. doi: https://doi.org/10.1002/ajh.24196Gotlib J. World Health Organization-defined eosinophilic disorders: 2015 update on diagnosis, risk stratification, and management. Am J Hematol. 2015;90(11):1077–1189. doi: https://doi.org/10.1002/ajh.24196Emmi G, Silvestri E, Marconi R, et al. First report of FIP1L1- PDGFRα-positive eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54(9):1751–1753. doi: https://doi.org/10.1093/rheumatology/kev242Emmi G, Silvestri E, Marconi R, et al. First report of FIP1L1- PDGFRα-positive eosinophilic granulomatosis with polyangiitis. Rheumatology (Oxford). 2015;54(9):1751–1753. doi: https://doi.org/10.1093/rheumatology/kev242Alzghoul BN, Reddy R, Chizinga M, et al. Pulmonary Embolism in Acute Asthma Exacerbation: Clinical Characteristics, Prediction Model and Hospital Outcomes. Lung. 2020;198(4):661–669. doi: https://doi.org/10.1007/s00408-020-00363-0Alzghoul BN, Reddy R, Chizinga M, et al. Pulmonary Embolism in Acute Asthma Exacerbation: Clinical Characteristics, Prediction Model and Hospital Outcomes. Lung. 2020;198(4):661–669. doi: https://doi.org/10.1007/s00408-020-00363-0Ayuk AC, Uwaezuoke SN, Ndukwu CI, et al. Spirometry in Asthma Care: A Review of the Trends and Challenges in Pediatric Practice. Clin Med Insights Pediatr. 2017;11:117955651772067. doi: https://doi.org/10.1177/1179556517720675Ayuk AC, Uwaezuoke SN, Ndukwu CI, et al. Spirometry in Asthma Care: A Review of the Trends and Challenges in Pediatric Practice. Clin Med Insights Pediatr. 2017;11:117955651772067. doi: https://doi.org/10.1177/1179556517720675Chhabra SK. Clinical application of spirometry in asthma: Why, when and how often? Lung India. 2015;32(6):635–637. doi: https://doi.org/10.4103/0970-2113.168139Chhabra SK. Clinical application of spirometry in asthma: Why, when and how often? Lung India. 2015;32(6):635–637. doi: https://doi.org/10.4103/0970-2113.168139Gallucci M, Carbonara P, Pacilli AMG, et al. Use of Symptoms Scores, Spirometry, and Other Pulmonary Function Testing for Asthma Monitoring. Front Pediat. 2019;7:54. doi: https://doi.org/10.3389/FPED.2019.00054Gallucci M, Carbonara P, Pacilli AMG, et al. Use of Symptoms Scores, Spirometry, and Other Pulmonary Function Testing for Asthma Monitoring. Front Pediat. 2019;7:54. doi: https://doi.org/10.3389/FPED.2019.00054Спирометрия: методические рекомендации / Российское респираторное общество; Российская ассоциация специалистов функциональной диагностики; Российское научное медицинское общество терапевтов. — 2023. — 64 с. Доступно по: https://spulmo.ru/upload/kr/Spirometria_2023.pdf. Ссылка активна на 22.06.2025.Spirometriya: Guidelines. Russian Respiratory Society; Russian Association of Functional Diagnostics Specialists; Russian Scientific Medical Society of Therapists. 2023. 63 p. (In Russ). Доступно по: https://spulmo.ru/upload/kr/Spirometria_2023.pdf. Ссылка активна на 22.06.2025.Каменева М.Ю., Черняк А.В., Айсанов З.Р. и др. Спирометрия: методическое руководство по проведению исследования и интерпретации результатов // Пульмонология. — 2023. — Т. 33. — № 3. — С. 307–340. — doi: https://doi.org/10.18093/08690189-2023-33-3-307-340Kameneva MYu, Cherniak AV, Aisanov ZR, et al. Spirometry: national guidelines for the testing and interpretation of results. Pulmonologiya. 2023;33(3):307–340. (In Russ). doi: https://doi.org/10.18093/08690189-2023-33-3-307-340Чучалин А.Г., Ай санов З.Р., Чикина С.Ю. и др. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии // Пульмонология. — 2014. — № 6. — С. 11–24. — doi: https://doi.org/10.18093/0869-0189-2014-0-6-11-24Chuchalin AG, Aysanov ZR, Chikina SYu, et al. Federal guidelines of Russian Respiratory Society on spirometry. Pulmonologiya. 2014;(6):11–24. (In Russ). doi: https://doi.org/10.18093/0869-0189-2014-0-6-11-24Graham BL, Steenbruggen I, Barjaktarevic IZ, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J R Crit Care Med. 2019;200(8):E70–E88. doi: https://doi.org/10.1164/RCCM.201908-1590STGraham BL, Steenbruggen I, Barjaktarevic IZ, et al. Standardization of Spirometry 2019 Update. An Official American Thoracic Society and European Respiratory Society Technical Statement. Am J R Crit Care Med. 2019;200(8):E70–E88. doi: https://doi.org/10.1164/RCCM.201908-1590STPellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Resp J. 2005;26(5):948–968. doi: https://doi.org/10.1183/09031936.05.00035205Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Resp J. 2005;26(5):948–968. doi: https://doi.org/10.1183/09031936.05.00035205Shipp CL, Gergen PJ, Gern JE, et al. Asthma Management in Children. J Allergy Clin Immunol Pract. 2023;11(1):9–18. doi: https://doi.org/10.1016/J.JAIP.2022.10.031Shipp CL, Gergen PJ, Gern JE, et al. Asthma Management in Children. J Allergy Clin Immunol Pract. 2023;11(1):9–18. doi: https://doi.org/10.1016/J.JAIP.2022.10.031Martin J, Townshend J, Brodlie M. Diagnosis and management of asthma in children. BMJ Paediatr Open. 2022;6(1):e001277. doi: https://doi.org/10.1136/BMJPO-2021-001277Martin J, Townshend J, Brodlie M. Diagnosis and management of asthma in children. BMJ Paediatr Open. 2022;6(1):e001277. doi: https://doi.org/10.1136/BMJPO-2021-001277Mishra A, Ugra D, Kumar U. Study of spirometry parameters in suspected asthmatic children in a tertiary care hospital. Int J Contemp Pediatric. 2020;7(5):1023. doi: https://doi.org/10.18203/2349-3291.IJCP20201631Mishra A, Ugra D, Kumar U. Study of spirometry parameters in suspected asthmatic children in a tertiary care hospital. Int J Contemp Pediatric. 2020;7(5):1023. doi: https://doi.org/10.18203/2349-3291.IJCP20201631Reddel H, Ware S, Marks G, et al. Differences between asthma exacerbations and poor asthma control. Lancet. 1999;353(9150):364–369. doi: https://doi.org/10.1016/S0140-6736(98)06128-5Reddel H, Ware S, Marks G, et al. Differences between asthma exacerbations and poor asthma control. Lancet. 1999;353(9150):364–369. doi: https://doi.org/10.1016/S0140-6736(98)06128-5Курбачева О.М., Павлова К.С. Федеральные клинические рекомендации. Аллерген-специфическая иммунотерапия // Российский аллергологический журнал. — 2016. — № 4-5. — С. 55–61.Kurbacheva OM, Pavlova KS. Federal Clinical Recommendations. Allergen-specific Immunotherapy. Russian Journal of Allergy. 2016;(4-5):55–61. (In Russ).Чучалин А., Черняк А., Чикина С. и др. Функциональная диагностика в пульмонологии: практическое руководство. — М.: Атмосфера; 2009. — 192 с.Chuchalin A, Chernyak A, Chikina S, et al. Funktsional’naya diagnostika v pul’monologii: A practical guide. Moscow: Atmosphere; 2009. 192 p. (In Russ).Tan WC, Vollmer WM, Lamprecht B, et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax. 2012;67(8):718–726. doi: https://doi.org/10.1136/THORAXJNL-2011-201445Tan WC, Vollmer WM, Lamprecht B, et al. Worldwide patterns of bronchodilator responsiveness: results from the Burden of Obstructive Lung Disease study. Thorax. 2012;67(8):718–726. doi: https://doi.org/10.1136/THORAXJNL-2011-201445Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2020;161(1):309–329. doi: https://doi.org/10.1164/AJRCCM.161.1.ATS11-99Crapo RO, Casaburi R, Coates AL, et al. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2020;161(1):309–329. doi: https://doi.org/10.1164/AJRCCM.161.1.ATS11-99Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. Eur Respir J. 2018;52(5):1801033. doi: https://doi.org/10.1183/13993003.01033-2018Hallstrand TS, Leuppi JD, Joos G, et al. ERS technical standard on bronchial challenge testing: pathophysiology and methodology of indirect airway challenge testing. Eur Respir J. 2018;52(5):1801033. doi: https://doi.org/10.1183/13993003.01033-2018Красновский А.Л., Григорьев С.П., Александров О.В. и др. Провокационные бронхоконстрикторные тесты в современной пульмонологической практике // РМЖ. — 2014. — № 4. — С. 41–46. — doi: https://doi.org/10.17816/rmj38189Krasnovskiy AL, Grigoriyev SP, Aleksandrov OV, et al. The provocation broncho-constricting tests in modern pulmonological practice. RMJ. 2014;(4):41–46. (In Russ). doi: https://doi.org/10.17816/rmj38189Ora J, De Marco P, Gabriele M, et al. Exercise-Induced Asthma: Managing Respiratory Issues in Athletes. J Funct Morphol Kinesiol. 2024;9(1):15. doi: https://doi.org/10.3390/jfmk9010015Ora J, De Marco P, Gabriele M, et al. Exercise-Induced Asthma: Managing Respiratory Issues in Athletes. J Funct Morphol Kinesiol. 2024;9(1):15. doi: https://doi.org/10.3390/jfmk9010015Swartz E, Lang D. When should a methacholine challenge be ordered for a patient with suspected asthma? Cleve Clin J Med. 2008;75(1):37–40. doi: https://doi.org/10.3949/CCJM.75.1.37Swartz E, Lang D. When should a methacholine challenge be ordered for a patient with suspected asthma? Cleve Clin J Med. 2008;75(1):37–40. doi: https://doi.org/10.3949/CCJM.75.1.37Dell SD, Bola SS, Foty RG, et al. Provocative dose of methacholine causing a 20% drop in FEV1 should be used to interpret methacholine challenge tests with modern nebulizers. Ann Am Thorac Soc. 2015;12(3):357–363. doi: https://doi.org/10.1513/AnnalsATS.201409-433OCDell SD, Bola SS, Foty RG, et al. Provocative dose of methacholine causing a 20% drop in FEV1 should be used to interpret methacholine challenge tests with modern nebulizers. Ann Am Thorac Soc. 2015;12(3):357–363. doi: https://doi.org/10.1513/AnnalsATS.201409-433OCСкороходкина О.В., Лунцов А.В. Бронхомоторные тесты в клинической диагностике бронхиальной астмы // Вестник современной клинической медицины. — 2012. — Т. 5. — № 2. — C. 24–29.Skorokhodkina OV, Luntsov AV. Challenge tests in clinical diagnostics of bronchial asthma. The Bulletin of Contemporary Clinical Medicine. 2012;5(2):24–29. (In Russ).Kussek P, Rosario Filho NA, Cat M. Bronchial hyperresponsiveness to hypertonic saline challenge in children and adolescents. J Bras Pneumol. 2006;32(2):195–201. doi: https://doi.org/10.1590/S1806-37132006000300004Kussek P, Rosario Filho NA, Cat M. Bronchial hyperresponsiveness to hypertonic saline challenge in children and adolescents. J Bras Pneumol. 2006;32(2):195–201. doi: https://doi.org/10.1590/S1806-37132006000300004Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49(5):1601526. doi: https://doi.org/10.1183/13993003.01526-2016Coates AL, Wanger J, Cockcroft DW, et al. ERS technical standard on bronchial challenge testing: general considerations and performance of methacholine challenge tests. Eur Respir J. 2017;49(5):1601526. doi: https://doi.org/10.1183/13993003.01526-2016Ramsdale EH, Morris MM, Roberts RS, Hargreave FE. Asymptomatic bronchial hyperresponsiveness in rhinitis. J Allergy Clin Immunol. 1985;75(5):573–577. doi: https://doi.org/10.1016/0091-6749(85)90032-6Ramsdale EH, Morris MM, Roberts RS, Hargreave FE. Asymptomatic bronchial hyperresponsiveness in rhinitis. J Allergy Clin Immunol. 1985;75(5):573–577. doi: https://doi.org/10.1016/0091-6749(85)90032-6Ramsdale EH, Morris MM, Roberts RS, Hargreave FE. Bronchial responsiveness to methacholine in chronic bronchitis: Relationship to airflow obstruction and cold air responsiveness. Thorax. 1984;39(12):912–918. doi: https://doi.org/10.1136/thx.39.12.912Ramsdale EH, Morris MM, Roberts RS, Hargreave FE. Bronchial responsiveness to methacholine in chronic bronchitis: Relationship to airflow obstruction and cold air responsiveness. Thorax. 1984;39(12):912–918. doi: https://doi.org/10.1136/thx.39.12.912van Haren EHJ, Lammers JWJ, Festen J, et al. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med. 1995;89(3):209–214. doi: https://doi.org/10.1016/0954-6111(95)90249-Xvan Haren EHJ, Lammers JWJ, Festen J, et al. The effects of the inhaled corticosteroid budesonide on lung function and bronchial hyperresponsiveness in adult patients with cystic fibrosis. Respir Med. 1995;89(3):209–214. doi: https://doi.org/10.1016/0954-6111(95)90249-XJoshi S, Powell T, Watkins WJ, et al. Exercise-induced bronchoconstriction in school-aged children who had chronic lung disease in infancy. J Pediatr. 2013;162(4):813–818.e1. doi: https://doi.org/10.1016/J.JPEDS.2012.09.040Joshi S, Powell T, Watkins WJ, et al. Exercise-induced bronchoconstriction in school-aged children who had chronic lung disease in infancy. J Pediatr. 2013;162(4):813–818.e1. doi: https://doi.org/10.1016/J.JPEDS.2012.09.040Nowak RM, Pensler MI, Sarkar DD, et al. Comparison of peak expiratory flow and FEV1 admission criteria for acute bronchial asthma. Ann Emerg Med. 1982;11(2):64–69. doi: https://doi.org/10.1016/S0196-0644(82)80298-9Nowak RM, Pensler MI, Sarkar DD, et al. Comparison of peak expiratory flow and FEV1 admission criteria for acute bronchial asthma. Ann Emerg Med. 1982;11(2):64–69. doi: https://doi.org/10.1016/S0196-0644(82)80298-9Reddel HK, Marks GB, Jenkins CR. When can personal best peak flow be determined for asthma action plans? Thorax. 2004;59(11): 922–924. doi: https://doi.org/10.1136/THX.2004.023077Reddel HK, Marks GB, Jenkins CR. When can personal best peak flow be determined for asthma action plans? Thorax. 2004;59(11): 922–924. doi: https://doi.org/10.1136/THX.2004.023077Лукина О.Ф., Фастовская А.М., Хан М.А. и др. Импульсная осциллометрия в оценке нарушений дыхания у детей с хроническими заболеваниями легких // Вопросы диагностики в педиат рии. — 2010. — Т. 2. — № 3. — С. 24–28.Lukina OF, Fastovskaya AM, Khan MA, et al. Pulse oscillometry in estimation of breath disorders in children with chronic lung diseases. Voprosy diagnostiki v pediatrii. 2010;2(3):24–28. (In Russ).Лукина О.Ф. Особенности исследования функции внешнего дыхания у детей и подростков // Практическая пульмонология. — 2017. — № 4. — С. 39–43.Lukina OF. Pulmonary Function Tests in Children and Adolescents. Prakticheskaya pulmonologiya. 2017;(4):39–43. (In Russ).Kim HY, Shin YH, Jung DW, et al. Resistance and reactance in oscillation lung function reflect basal lung function and bronchial hyperresponsiveness respectively. Respirology. 2009;14(7):1035– 1041. doi: https://doi.org/10.1111/J.1440-1843.2009.01605.XKim HY, Shin YH, Jung DW, et al. Resistance and reactance in oscillation lung function reflect basal lung function and bronchial hyperresponsiveness respectively. Respirology. 2009;14(7):1035– 1041. doi: https://doi.org/10.1111/J.1440-1843.2009.01605.XKonstantinou GN, Xepapadaki P, Papadopoulos NG, Manousakis E. Virus-Induced Asthma/Wheeze in Preschool Children: Longitudinal Assessment of Airflow Limitation Using Impulse Oscillometry. J Clin Med. 2019;8(9):1475. doi: https://doi.org/10.3390/JCM8091475Konstantinou GN, Xepapadaki P, Papadopoulos NG, Manousakis E. Virus-Induced Asthma/Wheeze in Preschool Children: Longitudinal Assessment of Airflow Limitation Using Impulse Oscillometry. J Clin Med. 2019;8(9):1475. doi: https://doi.org/10.3390/JCM8091475Rupani H, Kent BD. Using Fractional Exhaled Nitric Oxide Measurement in Clinical Asthma Management. Chest. 2022;161(4):906–917. doi: https://doi.org/10.1016/J.CHEST.2021.10.015Rupani H, Kent BD. Using Fractional Exhaled Nitric Oxide Measurement in Clinical Asthma Management. Chest. 2022;161(4):906–917. doi: https://doi.org/10.1016/J.CHEST.2021.10.015Di Cicco M, Peroni DG, Ragazzo V, Comberiati P. Application of exhaled nitric oxide (FeNO) in pediatric asthma. Curr Opin Allergy Clin Immunol. 2021;21(2):151–158. doi: https://doi.org/10.1097/ACI.0000000000000726Di Cicco M, Peroni DG, Ragazzo V, Comberiati P. Application of exhaled nitric oxide (FeNO) in pediatric asthma. Curr Opin Allergy Clin Immunol. 2021;21(2):151–158. doi: https://doi.org/10.1097/ACI.0000000000000726Ferraro V, Carraro S, Bozzetto S, et al. Exhaled biomarkers in childhood asthma: old and new approaches. Asthma Res Pract. 2018;4(1):9. doi: https://doi.org/10.1186/S40733-018-0045-6Ferraro V, Carraro S, Bozzetto S, et al. Exhaled biomarkers in childhood asthma: old and new approaches. Asthma Res Pract. 2018;4(1):9. doi: https://doi.org/10.1186/S40733-018-0045-6Singer F, Luchsinger I, Inci D, et al. Exhaled nitric oxide in symptomatic children at preschool age predicts later asthma. Allergy. 2013;68(4):531–538. doi: https://doi.org/10.1111/ALL.12127Singer F, Luchsinger I, Inci D, et al. Exhaled nitric oxide in symptomatic children at preschool age predicts later asthma. Allergy. 2013;68(4):531–538. doi: https://doi.org/10.1111/ALL.12127Chien JW, Ciufo R, Novak R, et al. Uncontrolled oxygen administration and respiratory failure in acute asthma. Chest. 2000;117(3):728–733. doi: https://doi.org/10.1378/CHEST.117.3.728Chien JW, Ciufo R, Novak R, et al. Uncontrolled oxygen administration and respiratory failure in acute asthma. Chest. 2000;117(3):728–733. doi: https://doi.org/10.1378/CHEST.117.3.728Lommatzsch SE, Martin RJ, Good JT Jr. Importance of fiberoptic bronchoscopy in identifying asthma phenotypes to direct personalized therapy. Curr Opin Pulm Med. 2013;19(1):42–48. doi: https://doi.org/10.1097/MCP.0b013e32835a5bdcLommatzsch SE, Martin RJ, Good JT Jr. Importance of fiberoptic bronchoscopy in identifying asthma phenotypes to direct personalized therapy. Curr Opin Pulm Med. 2013;19(1):42–48. doi: https://doi.org/10.1097/MCP.0b013e32835a5bdcBen Tkhayat R, Taytard J, Corvol H, et al. Benefits and risks of bronchoalveolar lavage in severe asthma in children. ERJ Open Res. 2021;7(4):00332-2021. doi: https://doi.org/10.1183/23120541.00332-2021Ben Tkhayat R, Taytard J, Corvol H, et al. Benefits and risks of bronchoalveolar lavage in severe asthma in children. ERJ Open Res. 2021;7(4):00332-2021. doi: https://doi.org/10.1183/23120541.00332-2021Steinke JW, Lawrence MG, Teague WG, et al. Bronchoalveolar lavage cytokine patterns in children with severe neutrophilic and paucigranulocytic asthma. J Allergy Clin Immunol. 2021;147(2): 686–693.e3. doi: https://doi.org/10.1016/j.jaci.2020.05.039Steinke JW, Lawrence MG, Teague WG, et al. Bronchoalveolar lavage cytokine patterns in children with severe neutrophilic and paucigranulocytic asthma. J Allergy Clin Immunol. 2021;147(2): 686–693.e3. doi: https://doi.org/10.1016/j.jaci.2020.05.039Коршунова Л.В., Урясьев О.М., Фоменко Н.П., Урясьева Ю.Б. Сочетание бронхиальной астмы и ГЭРБ // Земский Врач. — 2015. — № 1. — С. 24–27.Korshunova LV, Uryasev OM, Fomenko NP, Uryaseva YuB. Comorbidity of bronchial asthma and gastroesophageal reflux disease. Zemskii Vrach. 2015;(1):24–27. (In Russ).Козлова И.В., Пахомова А.Л., Кветной И.М. Бронхиальная астма и ГЭРБ с рефлюкс-эзофагитом: клинические и морфологические особенности сочетанной патологии // Экспериментальная и клиническая гастроэнтерология. — 2014. — Т. 106. — № 6. — С. 33–37.Kozlova IV, Pakhomova AL, Kvetnoy IM. Asthma and gerd with reflux esophagitis: clinical and morphological specialties of comorbidity. Experimental and Clinical Gastroenterology. 2014;106(6):33–37. (In Russ).Amarasiri DL, Pathmeswaran A, Dassanayake AS, et al. Esophageal motility, vagal function and gastroesophageal reflux in a cohort of adult asthmatics. BMC Gastroenterol. 2012;12:140. doi: https://doi.org/10.1186/1471-230X-12-140Amarasiri DL, Pathmeswaran A, Dassanayake AS, et al. Esophageal motility, vagal function and gastroesophageal reflux in a cohort of adult asthmatics. BMC Gastroenterol. 2012;12:140. doi: https://doi.org/10.1186/1471-230X-12-140Sontag SJ, O’Connell S, Khandelwal S, et al. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol. 2003;98(5):987–999. doi: https://doi.org/10.1111/j.1572-0241.2003.07503.xSontag SJ, O’Connell S, Khandelwal S, et al. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol. 2003;98(5):987–999. doi: https://doi.org/10.1111/j.1572-0241.2003.07503.xVakil N, van Zanten SV, Kahrilas P, et al. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol. 2006;101(8):1900–1920; quiz 1943. doi: https://doi.org/10.1111/j.1572-0241.2006.00630.xVakil N, van Zanten SV, Kahrilas P, et al. The Montreal Definition and Classification of Gastroesophageal Reflux Disease: A Global Evidence-Based Consensus. Am J Gastroenterol. 2006;101(8):1900–1920; quiz 1943. doi: https://doi.org/10.1111/j.1572-0241.2006.00630.xLiang B, Yi Q, Feng Y. Association of gastroesophageal reflux disease with asthma control. Dis Esophagus. 2013;26(8):794–798. doi: https://doi.org/10.1111/j.1442-2050.2012.01399.xLiang B, Yi Q, Feng Y. Association of gastroesophageal reflux disease with asthma control. Dis Esophagus. 2013;26(8):794–798. doi: https://doi.org/10.1111/j.1442-2050.2012.01399.xArshad H, Khan RR, Khaja M. Case Report of S1Q3T3 Electrocardiographic Abnormality in a Pregnant Asthmatic Patient During Acute Bronchospasm. Am J Case Rep. 2017;18:110–113. doi: https://doi.org/10.12659/ajcr.901661Arshad H, Khan RR, Khaja M. Case Report of S1Q3T3 Electrocardiographic Abnormality in a Pregnant Asthmatic Patient During Acute Bronchospasm. Am J Case Rep. 2017;18:110–113. doi: https://doi.org/10.12659/ajcr.901661Абрамовская К.Д., Туш Е.В., Болдова М.В. и др. Взаимосвязь спирометрических данных и параметров ЭКГ у детей с бронхиальной астмой // Аллергология и иммунология в педиатрии. — 2022. — № 2. — С. 27–29. — doi: https://doi.org/10.53529/2500-1175-2022-2-27-29Abramovskaya KD, Tush EV, Boldova MV, et al. Relationship between the spirometric parameters and ECG parameters in children with bronchial asthma. Allergology and Immunology in Pediatrics. 2022;(2):27–29. (In Russ). doi: https://doi.org/10.53529/2500-1175-2022-2-27-29Yalta K, Yalta T, Gurdogan M, et al. Cardiac Biomarkers in the Setting of Asthma Exacerbations: a Review of Clinical Implications and Practical Considerations. Curr Allergy Asthma Rep. 2020; 20(6):17. doi: https://doi.org/10.1007/s11882-020-00909-5Yalta K, Yalta T, Gurdogan M, et al. Cardiac Biomarkers in the Setting of Asthma Exacerbations: a Review of Clinical Implications and Practical Considerations. Curr Allergy Asthma Rep. 2020; 20(6):17. doi: https://doi.org/10.1007/s11882-020-00909-5McDonald NJ, Bara AI. Anticholinergic therapy for chronic asthma in children over two years of age. Cochrane Database Syst Rev. 2003;2003(3):CD003535. doi: https://doi.org/10.1002/14651858.CD003535McDonald NJ, Bara AI. Anticholinergic therapy for chronic asthma in children over two years of age. Cochrane Database Syst Rev. 2003;2003(3):CD003535. doi: https://doi.org/10.1002/14651858.CD003535White CS, Cole RP, Lubetsky HW, Austin JHM. Acute asthma. Admission chest radiography in hospitalized adult patients. Chest. 1991;100(1):14–16. doi: https://doi.org/10.1378/CHEST.100.1.14White CS, Cole RP, Lubetsky HW, Austin JHM. Acute asthma. Admission chest radiography in hospitalized adult patients. Chest. 1991;100(1):14–16. doi: https://doi.org/10.1378/CHEST.100.1.14Trottier ED, Chan K, Allain D, Chauvin-Kimoff L. Managing an acute asthma exacerbation in children. Paediatr Child Health. 2021;26(7):438–438. doi: https://doi.org/10.1093/PCH/PXAB058Trottier ED, Chan K, Allain D, Chauvin-Kimoff L. Managing an acute asthma exacerbation in children. Paediatr Child Health. 2021;26(7):438–438. doi: https://doi.org/10.1093/PCH/PXAB058Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic Endotypes and Phenotypes of Asthma. J Allergy Clinl Immunol Pract. 2020;8(2):429–440. doi: https://doi.org/10.1016/J.JAIP.2019.11.008Akar-Ghibril N, Casale T, Custovic A, Phipatanakul W. Allergic Endotypes and Phenotypes of Asthma. J Allergy Clinl Immunol Pract. 2020;8(2):429–440. doi: https://doi.org/10.1016/J.JAIP.2019.11.008Dibek Misirlioğlu E, Reha Cengizlier M. Skin prick test results of child patients diagnosed with bronchial asthma. Allergol Immunopathol (Madr). 2007;35(1):21–24. doi: https://doi.org/10.1157/13099091Dibek Misirlioğlu E, Reha Cengizlier M. Skin prick test results of child patients diagnosed with bronchial asthma. Allergol Immunopathol (Madr). 2007;35(1):21–24. doi: https://doi.org/10.1157/13099091Bousquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012;67(1):18– 24. doi: https://doi.org/10.1111/J.1398-9995.2011.02728.XBousquet J, Heinzerling L, Bachert C, et al. Practical guide to skin prick tests in allergy to aeroallergens. Allergy. 2012;67(1):18– 24. doi: https://doi.org/10.1111/J.1398-9995.2011.02728.XMapp CE, Boschetto P, Maestrelli P, Fabbri LM. Occupational asthma. Am J Respir Crit Care Med. 2005;172(3):280–305. doi: https://doi.org/10.1164/RCCM.200311-1575SOMapp CE, Boschetto P, Maestrelli P, Fabbri LM. Occupational asthma. Am J Respir Crit Care Med. 2005;172(3):280–305. doi: https://doi.org/10.1164/RCCM.200311-1575SOBaur X, Sigsgaard T, Aasen TB, et al. Guidelines for the management of work-related asthma. Eur Respir J. 2012;39(3): 529–545. doi: https://doi.org/10.1183/09031936.00096111Baur X, Sigsgaard T, Aasen TB, et al. Guidelines for the management of work-related asthma. Eur Respir J. 2012;39(3): 529–545. doi: https://doi.org/10.1183/09031936.00096111Park D, Moore VC, Burge CBSG, et al. Serial PEF measurement is superior to crossshift change in diagnosing occupational asthma. Eur Respir J. 2009;34(3):574–578. doi: https://doi.org/10.1183/09031936.00150108Park D, Moore VC, Burge CBSG, et al. Serial PEF measurement is superior to crossshift change in diagnosing occupational asthma. Eur Respir J. 2009;34(3):574–578. doi: https://doi.org/10.1183/09031936.00150108Malo JL, Cartier A, L’Archeveque J, et al. How many times per day should peak expiratory flow rates be assessed when investigating occupational asthma? Thorax. 1993;48(12): 1211–1217. doi: https://doi.org/10.1136/THX.48.12.1211Malo JL, Cartier A, L’Archeveque J, et al. How many times per day should peak expiratory flow rates be assessed when investigating occupational asthma? Thorax. 1993;48(12): 1211–1217. doi: https://doi.org/10.1136/THX.48.12.1211Cebrail S, Bilge A, Gulden S. Comparison of Specific Inhalation Challenge Test Results in Occupational and NonOccupational Asthma Patients: Is Monitoring Peak Expiratory Flow Rate Sufficient for Diagnosis? Int J Respir Pulm Med. 2021;5(4):555666. doi: https://doi.org/10.19080/IJOPRS.2021.05.555666Cebrail S, Bilge A, Gulden S. Comparison of Specific Inhalation Challenge Test Results in Occupational and NonOccupational Asthma Patients: Is Monitoring Peak Expiratory Flow Rate Sufficient for Diagnosis? Int J Respir Pulm Med. 2021;5(4):555666. doi: https://doi.org/10.19080/IJOPRS.2021.05.555666DiMango E, Rogers L, Reibman J, et al. Risk Factors for Asthma Exacerbation and Treatment Failure in Adults and Adolescents with Well-controlled Asthma during Continuation and Step-Down Therapy. Ann Am Thorac Soc. 2018;15(8):955–961. doi: https://doi.org/10.1513/ANNALSATS.201711-886OCDiMango E, Rogers L, Reibman J, et al. Risk Factors for Asthma Exacerbation and Treatment Failure in Adults and Adolescents with Well-controlled Asthma during Continuation and Step-Down Therapy. Ann Am Thorac Soc. 2018;15(8):955–961. doi: https://doi.org/10.1513/ANNALSATS.201711-886OCUsmani OS, Kemppinen A, Gardener E, et al. A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/ Formoterol in Asthma. J Allergy Clin Immunol Pract. 2017;5(5): 1378–1387.e5. doi: https://doi.org/10.1016/J.JAIP.2017.02.006Usmani OS, Kemppinen A, Gardener E, et al. A Randomized Pragmatic Trial of Changing to and Stepping Down Fluticasone/ Formoterol in Asthma. J Allergy Clin Immunol Pract. 2017;5(5): 1378–1387.e5. doi: https://doi.org/10.1016/J.JAIP.2017.02.006Ducharme FM, Zemek R, Chauhan BF, et al. Factors associated with failure of emergency department management in children with acute moderate or severe asthma: a prospective, multicentre, cohort study. Lancet Respir Med. 2016;4(12):990–998. doi: https://doi.org/10.1016/S2213-2600(16)30160-6Ducharme FM, Zemek R, Chauhan BF, et al. Factors associated with failure of emergency department management in children with acute moderate or severe asthma: a prospective, multicentre, cohort study. Lancet Respir Med. 2016;4(12):990–998. doi: https://doi.org/10.1016/S2213-2600(16)30160-6Alimani GS, Ananth S, Boccabella C, et al. Prevalence and clinical implications of respiratory viruses in asthma during stable disease state and acute attacks: Protocol for a meta-analysis. PLoS One. 2023;18(11):e0294416. doi: https://doi.org/10.1371/journal.pone.0294416Alimani GS, Ananth S, Boccabella C, et al. Prevalence and clinical implications of respiratory viruses in asthma during stable disease state and acute attacks: Protocol for a meta-analysis. PLoS One. 2023;18(11):e0294416. doi: https://doi.org/10.1371/journal.pone.0294416Xiong S, Chen W, Jia X, et al. Machine learning for prediction of asthma exacerbations among asthmatic patients: a systematic review and meta-analysis. BMC Pulm Med. 2023;23(1):278. doi: https://doi.org/10.1186/s12890-023-02570-wXiong S, Chen W, Jia X, et al. Machine learning for prediction of asthma exacerbations among asthmatic patients: a systematic review and meta-analysis. BMC Pulm Med. 2023;23(1):278. doi: https://doi.org/10.1186/s12890-023-02570-wCastillo JR, Peters SP, Busse WW. Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. J Allergy Clin Immunol Pract. 2017;5(4):918–927. doi: https://doi.org/10.1016/J.JAIP.2017.05.001Castillo JR, Peters SP, Busse WW. Asthma Exacerbations: Pathogenesis, Prevention, and Treatment. J Allergy Clin Immunol Pract. 2017;5(4):918–927. doi: https://doi.org/10.1016/J.JAIP.2017.05.001Robijn AL, Bokern MP, Jensen ME, et al. Risk factors for asthma exacerbations during pregnancy: a systematic review and metaanalysis. Eur Respir Rev. 2022;31(164):220039. doi: https://doi.org/10.1183/16000617.0039-2022Robijn AL, Bokern MP, Jensen ME, et al. Risk factors for asthma exacerbations during pregnancy: a systematic review and metaanalysis. Eur Respir Rev. 2022;31(164):220039. doi: https://doi.org/10.1183/16000617.0039-2022Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med. 2001;163(2):406–412. doi: https://doi.org/10.1164/AJRCCM.163.2.9912091Leuppi JD, Salome CM, Jenkins CR, et al. Predictive markers of asthma exacerbation during stepwise dose reduction of inhaled corticosteroids. Am J Respir Crit Care Med. 2001;163(2):406–412. doi: https://doi.org/10.1164/AJRCCM.163.2.9912091Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev. 2021;5(5):CD013518. doi: https://doi.org/10.1002/14651858.CD013518.pub2Crossingham I, Turner S, Ramakrishnan S, et al. Combination fixed-dose beta agonist and steroid inhaler as required for adults or children with mild asthma. Cochrane Database Syst Rev. 2021;5(5):CD013518. doi: https://doi.org/10.1002/14651858.CD013518.pub2Krings JG, Beasley R. The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today. J Allergy Clin Immunol Pract. 2024;12(4):870–879. doi: https://doi.org/10.1016/J.JAIP.2024.01.011Krings JG, Beasley R. The Role of ICS-Containing Rescue Therapy Versus SABA Alone in Asthma Management Today. J Allergy Clin Immunol Pract. 2024;12(4):870–879. doi: https://doi.org/10.1016/J.JAIP.2024.01.011Domingo C, Singh D. The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription. Adv Ther. 2023;40(4):1301–1316. doi: https://doi.org/10.1007/s12325-022-02410-zDomingo C, Singh D. The Changing Asthma Management Landscape and Need for Appropriate SABA Prescription. Adv Ther. 2023;40(4):1301–1316. doi: https://doi.org/10.1007/s12325-022-02410-zBeasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. New Eng J Med. 2019;380(21):2020–2030. doi: https://doi.org/10.1056/NEJMOA1901963Beasley R, Holliday M, Reddel HK, et al. Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma. New Eng J Med. 2019;380(21):2020–2030. doi: https://doi.org/10.1056/NEJMOA1901963O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. New Eng J Med. 2018;378(20):1865–1876. doi: https://doi.org/10.1056/NEJMOA1715274O’Byrne PM, FitzGerald JM, Bateman ED, et al. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. New Eng J Med. 2018;378(20):1865–1876. doi: https://doi.org/10.1056/NEJMOA1715274Bateman ED, Reddel HK, O’Byrne PM, et al. As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma. New Eng J Med. 2018;378(20):1877–1887. doi: https://doi.org/10.1056/nejmoa1715275Bateman ED, Reddel HK, O’Byrne PM, et al. As-Needed Budesonide–Formoterol versus Maintenance Budesonide in Mild Asthma. New Eng J Med. 2018;378(20):1877–1887. doi: https://doi.org/10.1056/nejmoa1715275Hatter L, Bruce P, Braithwaite I, et al. ICS-formoterol reliever versus ICS and short-acting β2-agonist reliever in asthma: a systematic review and meta-analysis. ERJ Open Res. 2021;7(1):00701–02020. doi: https://doi.org/10.1183/23120541.00701-2020Hatter L, Bruce P, Braithwaite I, et al. ICS-formoterol reliever versus ICS and short-acting β2-agonist reliever in asthma: a systematic review and meta-analysis. ERJ Open Res. 2021;7(1):00701–02020. doi: https://doi.org/10.1183/23120541.00701-2020Stanford RH, Shah MB, D’Souza AO, et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–407. doi: https://doi.org/10.1016/J.ANAI.2012.08.014Stanford RH, Shah MB, D’Souza AO, et al. Short-acting β-agonist use and its ability to predict future asthma-related outcomes. Ann Allergy Asthma Immunol. 2012;109(6):403–407. doi: https://doi.org/10.1016/J.ANAI.2012.08.014Bhagat R, Swystun VA, Cockcroft DW. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J Allergy Clin Immunol. 1996;97 (1 Pt 1):47–52. doi: https://doi.org/10.1016/S0091-6749(96)70282-8Bhagat R, Swystun VA, Cockcroft DW. Salbutamol-induced increased airway responsiveness to allergen and reduced protection versus methacholine: dose response. J Allergy Clin Immunol. 1996;97 (1 Pt 1):47–52. doi: https://doi.org/10.1016/S0091-6749(96)70282-8Hancox RJ, Cowan JO, Flannery EM, et al. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med. 2000;94(8):767–771. doi: https://doi.org/10.1053/RMED.2000.0820Hancox RJ, Cowan JO, Flannery EM, et al. Bronchodilator tolerance and rebound bronchoconstriction during regular inhaled beta-agonist treatment. Respir Med. 2000;94(8):767–771. doi: https://doi.org/10.1053/RMED.2000.0820Kraft M, Richardson M, Hallmark B, et al. The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study. Lancet Respir Med. 2022;10(7):661–668. doi: https://doi.org/10.1016/S2213-2600(21)00536-1Kraft M, Richardson M, Hallmark B, et al. The role of small airway dysfunction in asthma control and exacerbations: a longitudinal, observational analysis using data from the ATLANTIS study. Lancet Respir Med. 2022;10(7):661–668. doi: https://doi.org/10.1016/S2213-2600(21)00536-1Amin S, Soliman M, McIvor A, et al. Usage Patterns of Short-Acting β2-Agonists and Inhaled Corticosteroids in Asthma: A Targeted Literature Review. J Allergy Clin Immunol Pract. 2020;8(8): 2556–2564.e8. doi: https://doi.org/10.1016/j.jaip.2020.03.013Amin S, Soliman M, McIvor A, et al. Usage Patterns of Short-Acting β2-Agonists and Inhaled Corticosteroids in Asthma: A Targeted Literature Review. J Allergy Clin Immunol Pract. 2020;8(8): 2556–2564.e8. doi: https://doi.org/10.1016/j.jaip.2020.03.013Cho YS, Oh YM. Dilemma of Asthma Treatment in Mild Patients. Tuberc Respir Dis (Seoul). 2019;82(3):190–193. doi: https://doi.org/10.4046/TRD.2018.0013Cho YS, Oh YM. Dilemma of Asthma Treatment in Mild Patients. Tuberc Respir Dis (Seoul). 2019;82(3):190–193. doi: https://doi.org/10.4046/TRD.2018.0013O’Byrne PM, Mejza F. Advances in the treatment of mild asthma: recent evidence. Pol Arch Inter Med. 2018;128(9): 545–549. doi: https://doi.org/10.20452/PAMW.4341O’Byrne PM, Mejza F. Advances in the treatment of mild asthma: recent evidence. Pol Arch Inter Med. 2018;128(9): 545–549. doi: https://doi.org/10.20452/PAMW.4341Papi A, Canonica GW, Maestrelli P, et al. Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma. New Eng J Med. 2007;356(20):2040–2052. doi: https://doi.org/10.1056/nejmoa063861Papi A, Canonica GW, Maestrelli P, et al. Rescue Use of Beclomethasone and Albuterol in a Single Inhaler for Mild Asthma. New Eng J Med. 2007;356(20):2040–2052. doi: https://doi.org/10.1056/nejmoa063861Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9766):650–657. doi: https://doi.org/10.1016/S0140-6736(10)62145-9Martinez FD, Chinchilli VM, Morgan WJ, et al. Use of beclomethasone dipropionate as rescue treatment for children with mild persistent asthma (TREXA): a randomised, double-blind, placebo-controlled trial. Lancet. 2011;377(9766):650–657. doi: https://doi.org/10.1016/S0140-6736(10)62145-9Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;2013(4):CD007313. doi: https://doi.org/10.1002/14651858.CD007313.pub3Cates CJ, Karner C. Combination formoterol and budesonide as maintenance and reliever therapy versus current best practice (including inhaled steroid maintenance), for chronic asthma in adults and children. Cochrane Database Syst Rev. 2013;2013(4):CD007313. doi: https://doi.org/10.1002/14651858.CD007313.pub3Reddel HK, Bateman ED, Schatz M, et al. A Practical Guide to Implementing SMART in Asthma Management. J Allergy Clin Immunol Pract. 2022;10(1S):S31–S38. doi: https://doi.org/10.1016/J.JAIP.2021.10.011Reddel HK, Bateman ED, Schatz M, et al. A Practical Guide to Implementing SMART in Asthma Management. J Allergy Clin Immunol Pract. 2022;10(1S):S31–S38. doi: https://doi.org/10.1016/J.JAIP.2021.10.011Ulmeanu R, Bloju S, Vittos O. Assessment of Symptoms Control, Pulmonary Function and Related Quality of Life in Asthmatic Patients Treated with Extrafine Beclomethasone Dipropionate/ Formoterol Fumarate 100/6 μg pMDI: Results of a Multicenter Observational Study in Romania (ALFRESCO Study). J Asthma Allergy. 2022;15:919–933. doi: https://doi.org/10.2147/JAA.S358798Ulmeanu R, Bloju S, Vittos O. Assessment of Symptoms Control, Pulmonary Function and Related Quality of Life in Asthmatic Patients Treated with Extrafine Beclomethasone Dipropionate/ Formoterol Fumarate 100/6 μg pMDI: Results of a Multicenter Observational Study in Romania (ALFRESCO Study). J Asthma Allergy. 2022;15:919–933. doi: https://doi.org/10.2147/JAA.S358798Sobieraj DM, Weeda ER, Nguyen E, et al. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018;319(14): 1485–1496. doi: https://doi.org/10.1001/JAMA.2018.2769Sobieraj DM, Weeda ER, Nguyen E, et al. Association of Inhaled Corticosteroids and Long-Acting β-Agonists as Controller and Quick Relief Therapy With Exacerbations and Symptom Control in Persistent Asthma: A Systematic Review and Meta-analysis. JAMA. 2018;319(14): 1485–1496. doi: https://doi.org/10.1001/JAMA.2018.2769Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res. 2011;12(1). doi: https://doi.org/10.1186/1465-9921-12-38Bateman ED, Harrison TW, Quirce S, et al. Overall asthma control achieved with budesonide/formoterol maintenance and reliever therapy for patients on different treatment steps. Respir Res. 2011;12(1). doi: https://doi.org/10.1186/1465-9921-12-38Chong J, Haran C, Asher I. Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults. Cochrane Database Syst Rev. 2014;2014(4):CD011032. doi: https://doi.org/10.1002/14651858.CD011032Chong J, Haran C, Asher I. Intermittent inhaled corticosteroid therapy versus placebo for persistent asthma in children and adults. Cochrane Database Syst Rev. 2014;2014(4):CD011032. doi: https://doi.org/10.1002/14651858.CD011032Sumino K, Bacharier LB, Taylor J, et al. A Pragmatic Trial of Symptom-Based Inhaled Corticosteroid Use in African-American Children with Mild Asthma. J Allergy Clin Immunol Pract. 2020;8(1): 176–185.e2. doi: https://doi.org/10.1016/J.JAIP.2019.06.030Sumino K, Bacharier LB, Taylor J, et al. A Pragmatic Trial of Symptom-Based Inhaled Corticosteroid Use in African-American Children with Mild Asthma. J Allergy Clin Immunol Pract. 2020;8(1): 176–185.e2. doi: https://doi.org/10.1016/J.JAIP.2019.06.030Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. Am J Resp Crit Care Med. 2000;162(4 Pt 1):1500–1506. doi: https://doi.org/10.1164/AJRCCM.162.4.2002019Nielsen KG, Bisgaard H. The effect of inhaled budesonide on symptoms, lung function, and cold air and methacholine responsiveness in 2- to 5-year-old asthmatic children. Am J Resp Crit Care Med. 2000;162(4 Pt 1):1500–1506. doi: https://doi.org/10.1164/AJRCCM.162.4.2002019Pao CS, McKenzie SA, Bisgaard H, Nielsen KG. Inhaled corticosteroids for persistent wheeze in preschool children [3] (multiple letters). Am J Respir Crit Care Med. 2001;163(5):1278. doi: https://doi.org/10.1164/ajrccm.163.5.1635cPao CS, McKenzie SA, Bisgaard H, Nielsen KG. Inhaled corticosteroids for persistent wheeze in preschool children [3] (multiple letters). Am J Respir Crit Care Med. 2001;163(5):1278. doi: https://doi.org/10.1164/ajrccm.163.5.1635cCastro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic review. Pediatr Pulmonol. 2018;53(12):1670–1677. doi: https://doi.org/10.1002/ppul.24176Castro-Rodriguez JA, Rodriguez-Martinez CE, Ducharme FM. Daily inhaled corticosteroids or montelukast for preschoolers with asthma or recurrent wheezing: A systematic review. Pediatr Pulmonol. 2018;53(12):1670–1677. doi: https://doi.org/10.1002/ppul.24176Zhang HP, Jia CE, Lv Y, et al. Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. Allergy Asthma Proc. 2014;35(4):278–287. doi: https://doi.org/10.2500/AAP.2014.35.3745Zhang HP, Jia CE, Lv Y, et al. Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. Allergy Asthma Proc. 2014;35(4):278–287. doi: https://doi.org/10.2500/AAP.2014.35.3745Mayoral K, Lizano-Barrantes C, Zamora V, et al. Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis. Eur Respir Rev. 2023;32(170):230124. doi: https://doi.org/10.1183/16000617.0124-2023Mayoral K, Lizano-Barrantes C, Zamora V, et al. Montelukast in paediatric asthma and allergic rhinitis: a systematic review and meta-analysis. Eur Respir Rev. 2023;32(170):230124. doi: https://doi.org/10.1183/16000617.0124-2023Kaiser SV, Huynh T, Bacharier LB, et al. Preventing Exacerbations in Preschoolers With Recurrent Wheeze: A Metaanalysis. Pediatrics. 2016;137(6):e20154496. doi: https://doi.org/10.1542/PEDS.2015-4496Kaiser SV, Huynh T, Bacharier LB, et al. Preventing Exacerbations in Preschoolers With Recurrent Wheeze: A Metaanalysis. Pediatrics. 2016;137(6):e20154496. doi: https://doi.org/10.1542/PEDS.2015-4496Szefler SJ, Baker JW, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol. 2007;120(5): 1043–1050. doi: https://doi.org/10.1016/J.JACI.2007.08.063Szefler SJ, Baker JW, Uryniak T, et al. Comparative study of budesonide inhalation suspension and montelukast in young children with mild persistent asthma. J Allergy Clin Immunol. 2007;120(5): 1043–1050. doi: https://doi.org/10.1016/J.JACI.2007.08.063Fitzpatrick AM, Jackson DJ, Mauger DT, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608–1618.e12. doi: https://doi.org/10.1016/J.JACI.2016.09.028Fitzpatrick AM, Jackson DJ, Mauger DT, et al. Individualized therapy for persistent asthma in young children. J Allergy Clin Immunol. 2016;138(6):1608–1618.e12. doi: https://doi.org/10.1016/J.JACI.2016.09.028Chauhan BF, Chartrand C, Ni Chroinin M, et al. Addition of longacting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2015;2015(11):CD007949. doi: https://doi.org/10.1002/14651858.CD007949.pub2Chauhan BF, Chartrand C, Ni Chroinin M, et al. Addition of longacting beta2-agonists to inhaled corticosteroids for chronic asthma in children. Cochrane Database Syst Rev. 2015;2015(11):CD007949. doi: https://doi.org/10.1002/14651858.CD007949.pub2Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010;2010(4):CD005533. doi: https://doi.org/10.1002/14651858.CD005533.PUB2Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled steroids versus higher dose inhaled steroids in adults and children with persistent asthma. Cochrane Database Syst Rev. 2010;2010(4):CD005533. doi: https://doi.org/10.1002/14651858.CD005533.PUB2Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009;2009(4):CD005307. doi: https://doi.org/10.1002/14651858.CD005307.pub2Ni Chroinin M, Greenstone I, Lasserson TJ, Ducharme FM. Addition of long-acting beta2-agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults and children. Cochrane Database Syst Rev. 2009;2009(4):CD005307. doi: https://doi.org/10.1002/14651858.CD005307.pub2Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;2010(5):CD005535. doi: https://doi.org/10.1002/14651858.cd005535.pub2Ducharme FM, Ni Chroinin M, Greenstone I, Lasserson TJ. Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children. Cochrane Database Syst Rev. 2010;2010(5):CD005535. doi: https://doi.org/10.1002/14651858.cd005535.pub2Greenstone II, Ni Chroinin M, Lasserson TJ, Ducharme F. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev. 2005;(4):CD005533. doi: https://doi.org/10.1002/14651858.cd005533Greenstone II, Ni Chroinin M, Lasserson TJ, Ducharme F. Combination of inhaled long-acting beta2-agonists and inhaled steroids versus higher dose of inhaled steroids in children and adults with persistent asthma. Cochrane Database Syst Rev. 2005;(4):CD005533. doi: https://doi.org/10.1002/14651858.cd005533Powell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust. 2003;178(5):223–225. doi: https://doi.org/10.5694/J.1326-5377.2003.TB05167.XPowell H, Gibson PG. Inhaled corticosteroid doses in asthma: an evidence-based approach. Med J Aust. 2003;178(5):223–225. doi: https://doi.org/10.5694/J.1326-5377.2003.TB05167.XSzefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109(3):410–418. doi: https://doi.org/10.1067/mai.2002.122635Szefler SJ, Martin RJ, King TS, et al. Significant variability in response to inhaled corticosteroids for persistent asthma. J Allergy Clin Immunol. 2002;109(3):410–418. doi: https://doi.org/10.1067/mai.2002.122635Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and highdose inhaled budesonide for moderate asthma. New Eng J Med. 1997;337(20):1412–1419. doi: https://doi.org/10.1056/NEJM199711133372002Evans DJ, Taylor DA, Zetterstrom O, et al. A comparison of low-dose inhaled budesonide plus theophylline and highdose inhaled budesonide for moderate asthma. New Eng J Med. 1997;337(20):1412–1419. doi: https://doi.org/10.1056/NEJM199711133372002Castro-Rodriguez JA, Custovic A, Ducharme FM. Treatment of asthma in young children: evidence-based recommendations. Asthma Res Pract. 2016;2(1):1–11. doi: https://doi.org/10.1186/S40733-016-0020-zCastro-Rodriguez JA, Custovic A, Ducharme FM. Treatment of asthma in young children: evidence-based recommendations. Asthma Res Pract. 2016;2(1):1–11. doi: https://doi.org/10.1186/S40733-016-0020-zCastro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics. 2009;123(3):e519–e525. doi: https://doi.org/10.1542/PEDS.2008-2867Castro-Rodriguez JA, Rodrigo GJ. Efficacy of inhaled corticosteroids in infants and preschoolers with recurrent wheezing and asthma: a systematic review with meta-analysis. Pediatrics. 2009;123(3):e519–e525. doi: https://doi.org/10.1542/PEDS.2008-2867Yoshihara S, Tsubaki T, Ikeda M, et al. The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age. Pediatr Allergy Immunol. 2019;30(2): 195–203. doi: https://doi.org/10.1111/PAI.13010Yoshihara S, Tsubaki T, Ikeda M, et al. The efficacy and safety of fluticasone/salmeterol compared to fluticasone in children younger than four years of age. Pediatr Allergy Immunol. 2019;30(2): 195–203. doi: https://doi.org/10.1111/PAI.13010Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;2016(1):CD011721. doi: https://doi.org/10.1002/14651858.CD011721.PUB2Kew KM, Dahri K. Long-acting muscarinic antagonists (LAMA) added to combination long-acting beta2-agonists and inhaled corticosteroids (LABA/ICS) versus LABA/ICS for adults with asthma. Cochrane Database Syst Rev. 2016;2016(1):CD011721. doi: https://doi.org/10.1002/14651858.CD011721.PUB2Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012. doi: https://doi.org/10.1016/S2213-2600(20)30190-9Kerstjens HAM, Maspero J, Chapman KR, et al. Once-daily, single-inhaler mometasone-indacaterol-glycopyrronium versus mometasone-indacaterol or twice-daily fluticasone-salmeterol in patients with inadequately controlled asthma (IRIDIUM): a randomised, double-blind, controlled phase 3 study. Lancet Respir Med. 2020;8(10):1000–1012. doi: https://doi.org/10.1016/S2213-2600(20)30190-9Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749. doi: https://doi.org/10.1016/S0140-6736(19)32215-9Virchow JC, Kuna P, Paggiaro P, et al. Single inhaler extrafine triple therapy in uncontrolled asthma (TRIMARAN and TRIGGER): two double-blind, parallel-group, randomised, controlled phase 3 trials. Lancet. 2019;394(10210):1737–1749. doi: https://doi.org/10.1016/S0140-6736(19)32215-9Agusti A, Fabbri L, Lahousse L, et al. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Allergy. 2022;77(4):1105–1113. doi: https://doi.org/10.1111/ALL.15076Agusti A, Fabbri L, Lahousse L, et al. Single inhaler triple therapy (SITT) in asthma: Systematic review and practice implications. Allergy. 2022;77(4):1105–1113. doi: https://doi.org/10.1111/ALL.15076Kim LHY, Saleh C, Whalen-Browne A, et al. Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. JAMA. 2021;325(24): 2466–2479. doi: https://doi.org/10.1001/JAMA.2021.7872Kim LHY, Saleh C, Whalen-Browne A, et al. Triple vs Dual Inhaler Therapy and Asthma Outcomes in Moderate to Severe Asthma: A Systematic Review and Meta-analysis. JAMA. 2021;325(24): 2466–2479. doi: https://doi.org/10.1001/JAMA.2021.7872Nakamura Y, Hozawa S, Sagara H, et al. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/ vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study. Curr Med Res Opin. 2021;37(9):1657–1665. doi: https://doi.org/10.1080/03007995.2021.1944849Nakamura Y, Hozawa S, Sagara H, et al. Efficacy and safety of once-daily, single-inhaler fluticasone furoate/umeclidinium/ vilanterol versus fluticasone furoate/vilanterol in Japanese patients with inadequately controlled asthma: the CAPTAIN study. Curr Med Res Opin. 2021;37(9):1657–1665. doi: https://doi.org/10.1080/03007995.2021.1944849Umeda A, Shimada H, Yamane T, et al. Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan. Front Physiol. 2023;14:1131949. doi: https://doi.org/10.3389/FPHYS.2023.1131949Umeda A, Shimada H, Yamane T, et al. Real-world effects of once-daily inhaled steroid (fluticasone furoate) combined with long-acting beta-2 agonist (vilanterol) and long-acting muscarinic antagonist (umeclidinium) on lung function tests of asthma patients in Japan. Front Physiol. 2023;14:1131949. doi: https://doi.org/10.3389/FPHYS.2023.1131949Siler TM, Kerwin E, Sousa AR, et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Respir Med. 2015;109(9):1155–1163. doi: https://doi.org/10.1016/j.rmed.2015.06.006Siler TM, Kerwin E, Sousa AR, et al. Efficacy and safety of umeclidinium added to fluticasone furoate/vilanterol in chronic obstructive pulmonary disease: Results of two randomized studies. Respir Med. 2015;109(9):1155–1163. doi: https://doi.org/10.1016/j.rmed.2015.06.006Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170: 106021. doi: https://doi.org/10.1016/J.RMED.2020.106021Gessner C, Kornmann O, Maspero J, et al. Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON). Respir Med. 2020;170: 106021. doi: https://doi.org/10.1016/J.RMED.2020.106021van Zyl-Smit RN, Krüll M, Gessner C, et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. Lancet Respir Med. 2020;8(10):987–999. doi: https://doi.org/10.1016/S2213-2600(20)30178-8van Zyl-Smit RN, Krüll M, Gessner C, et al. Once-daily mometasone plus indacaterol versus mometasone or twice-daily fluticasone plus salmeterol in patients with inadequately controlled asthma (PALLADIUM): a randomised, double-blind, triple-dummy, controlled phase 3 study. Lancet Respir Med. 2020;8(10):987–999. doi: https://doi.org/10.1016/S2213-2600(20)30178-8Kerstjens HAM, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3(5):367–376. doi: https://doi.org/10.1016/S2213-2600(15)00031-4Kerstjens HAM, Casale TB, Bleecker ER, et al. Tiotropium or salmeterol as add-on therapy to inhaled corticosteroids for patients with moderate symptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet Respir Med. 2015;3(5):367–376. doi: https://doi.org/10.1016/S2213-2600(15)00031-4Timmer W, Moroni-Zentgraf P, Cornelissen P, et al. Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. Respir Med. 2015;109(3): 329–338. doi: https://doi.org/10.1016/j.rmed.2014.12.005Timmer W, Moroni-Zentgraf P, Cornelissen P, et al. Once-daily tiotropium Respimat® 5 μg is an efficacious 24-h bronchodilator in adults with symptomatic asthma. Respir Med. 2015;109(3): 329–338. doi: https://doi.org/10.1016/j.rmed.2014.12.005Rodrigo GJ, Neffen H. Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review. Pediatr Allergy Immunol. 2017;28(6):573–578. doi: https://doi.org/10.1111/pai.12759Rodrigo GJ, Neffen H. Efficacy and safety of tiotropium in school-age children with moderate-to-severe symptomatic asthma: A systematic review. Pediatr Allergy Immunol. 2017;28(6):573–578. doi: https://doi.org/10.1111/pai.12759Ohta K, Ichinose M, Tohda Y, et al. Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: A randomised, placebo-controlled study. PLoS One. 2015;10(4):e0124109. doi: https://doi.org/10.1371/journal.pone.0124109Ohta K, Ichinose M, Tohda Y, et al. Long-term once-daily tiotropium Respimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: A randomised, placebo-controlled study. PLoS One. 2015;10(4):e0124109. doi: https://doi.org/10.1371/journal.pone.0124109Kew KM, Evans DJ, Allison DE, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database Syst Rev. 2015;2015(6):CD011438. doi: https://doi.org/10.1002/14651858.CD011438.pub2Kew KM, Evans DJ, Allison DE, Boyter AC. Long-acting muscarinic antagonists (LAMA) added to inhaled corticosteroids (ICS) versus addition of long-acting beta2-agonists (LABA) for adults with asthma. Cochrane Database Syst Rev. 2015;2015(6):CD011438. doi: https://doi.org/10.1002/14651858.CD011438.pub2Löfdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999;319(7202):87–90. doi: https://doi.org/10.1136/BMJ.319.7202.87Löfdahl CG, Reiss TF, Leff JA, et al. Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients. BMJ. 1999;319(7202):87–90. doi: https://doi.org/10.1136/BMJ.319.7202.87Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58(3):211–216. doi: https://doi.org/10.1136/THORAX.58.3.211Price DB, Hernandez D, Magyar P, et al. Randomised controlled trial of montelukast plus inhaled budesonide versus double dose inhaled budesonide in adult patients with asthma. Thorax. 2003;58(3):211–216. doi: https://doi.org/10.1136/THORAX.58.3.211Vaquerizo MJ, Gonzalez-Esteban J, Casan P, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003;58(3):204–210. doi: https://doi.org/10.1136/THORAX.58.3.204Vaquerizo MJ, Gonzalez-Esteban J, Casan P, et al. Effect of montelukast added to inhaled budesonide on control of mild to moderate asthma. Thorax. 2003;58(3):204–210. doi: https://doi.org/10.1136/THORAX.58.3.204Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med. 1997;155(4):1235–1240. doi: https://doi.org/10.1164/AJRCCM.155.4.9105060Tamaoki J, Kondo M, Sakai N, et al. Leukotriene antagonist prevents exacerbation of asthma during reduction of high-dose inhaled corticosteroid. The Tokyo Joshi-Idai Asthma Research Group. Am J Respir Crit Care Med. 1997;155(4):1235–1240. doi: https://doi.org/10.1164/AJRCCM.155.4.9105060Ye Q, He XO, D’Urzo A. A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma. Pulm Ther. 2017;3(1):1–18. doi: https://doi.org/10.1007/S41030-017-0043-5Ye Q, He XO, D’Urzo A. A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma. Pulm Ther. 2017;3(1):1–18. doi: https://doi.org/10.1007/S41030-017-0043-5Malo JL, Cartier A, Ghezzo H, et al. Comparison of four-timesa-day and twice-a-day dosing regimens in subjects requiring 1200 micrograms or less of budesonide to control mild to moderate asthma. Respir Med. 1995;89(8):537–543. doi: https://doi.org/10.1016/0954-6111(95)90154-XMalo JL, Cartier A, Ghezzo H, et al. Comparison of four-timesa-day and twice-a-day dosing regimens in subjects requiring 1200 micrograms or less of budesonide to control mild to moderate asthma. Respir Med. 1995;89(8):537–543. doi: https://doi.org/10.1016/0954-6111(95)90154-XToogood JH, Baskerville JC, Jennings B, et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol. 1982;70(4):288–298. doi: https://doi.org/10.1016/0091-6749(82)90065-3Toogood JH, Baskerville JC, Jennings B, et al. Influence of dosing frequency and schedule on the response of chronic asthmatics to the aerosol steroid, budesonide. J Allergy Clin Immunol. 1982;70(4):288–298. doi: https://doi.org/10.1016/0091-6749(82)90065-3Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;2014(1):CD003559. doi: https://doi.org/10.1002/14651858.CD003559.PUB4Normansell R, Walker S, Milan SJ, et al. Omalizumab for asthma in adults and children. Cochrane Database Syst Rev. 2014;2014(1):CD003559. doi: https://doi.org/10.1002/14651858.CD003559.PUB4Farne HA, Wilson A, Milan S, et al. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev. 2022;7(7):CD010834. doi: https://doi.org/10.1002/14651858.CD010834.pub4Farne HA, Wilson A, Milan S, et al. Anti-IL-5 therapies for asthma. Cochrane Database Syst Rev. 2022;7(7):CD010834. doi: https://doi.org/10.1002/14651858.CD010834.pub4Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev. 2015;2015(7):CD010834. doi: https://doi.org/10.1002/14651858.CD010834.pub2Powell C, Milan SJ, Dwan K, et al. Mepolizumab versus placebo for asthma. Cochrane Database Syst Rev. 2015;2015(7):CD010834. doi: https://doi.org/10.1002/14651858.CD010834.pub2Xiong XF, Zhu M, Wu HX, et al. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. Respir Res. 2019;20(1):108. doi: https://doi.org/10.1186/S12931-019-1065-3Xiong XF, Zhu M, Wu HX, et al. Efficacy and safety of dupilumab for the treatment of uncontrolled asthma: a meta-analysis of randomized clinical trials. Respir Res. 2019;20(1):108. doi: https://doi.org/10.1186/S12931-019-1065-3Li J, Wang F, Lin C, et al. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis. J Asthma. 2017;54(3):300–307. doi: https://doi.org/10.1080/02770903.2016.1212371Li J, Wang F, Lin C, et al. The efficacy and safety of reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: A systematic review and meta-analysis. J Asthma. 2017;54(3):300–307. doi: https://doi.org/10.1080/02770903.2016.1212371Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. doi: https://doi.org/10.1016/S0140-6736(16)30307-5Wenzel S, Castro M, Corren J, et al. Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting β2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet. 2016;388(10039):31–44. doi: https://doi.org/10.1016/S0140-6736(16)30307-5Corren J, Karpefors M, Hellqvist Å, et al. Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study. J Asthma Allergy. 2021;14:1–11. doi: https://doi.org/10.2147/JAA.S286036Corren J, Karpefors M, Hellqvist Å, et al. Tezepelumab Reduces Exacerbations Across All Seasons in Patients with Severe, Uncontrolled Asthma: A Post Hoc Analysis of the PATHWAY Phase 2b Study. J Asthma Allergy. 2021;14:1–11. doi: https://doi.org/10.2147/JAA.S286036Busse WW, Castro M, Casale TB. Asthma Management in Adults. J Allergy Clinl Immunol Pract. 2023;11(1):21–33. doi: https://doi.org/10.1016/J.JAIP.2022.10.015Busse WW, Castro M, Casale TB. Asthma Management in Adults. J Allergy Clinl Immunol Pract. 2023;11(1):21–33. doi: https://doi.org/10.1016/J.JAIP.2022.10.015Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines — recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5): 1023–1042. doi: https://doi.org/10.1111/all.14221Agache I, Beltran J, Akdis C, et al. Efficacy and safety of treatment with biologicals (benralizumab, dupilumab, mepolizumab, omalizumab and reslizumab) for severe eosinophilic asthma. A systematic review for the EAACI Guidelines — recommendations on the use of biologicals in severe asthma. Allergy. 2020;75(5): 1023–1042. doi: https://doi.org/10.1111/all.14221Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47–58. doi: https://doi.org/10.1016/S2213-2600(21)00352-0Menzies-Gow A, Gurnell M, Heaney LG, et al. Oral corticosteroid elimination via a personalised reduction algorithm in adults with severe, eosinophilic asthma treated with benralizumab (PONENTE): a multicentre, open-label, single-arm study. Lancet Respir Med. 2022;10(1):47–58. doi: https://doi.org/10.1016/S2213-2600(21)00352-0Chheang C, Guinand S, von Garnier C, Sartori C. New perspectives of biological therapy for severe asthma in adults and adolescents. Swiss Med Week. 2022;152:w30176. doi: https://doi.org/10.4414/SMW.2022.W30176Chheang C, Guinand S, von Garnier C, Sartori C. New perspectives of biological therapy for severe asthma in adults and adolescents. Swiss Med Week. 2022;152:w30176. doi: https://doi.org/10.4414/SMW.2022.W30176Wangberg H, Woessner K. Choice of biologics in asthma endotypes. Curr Opin Allergy Clin Immunol. 2021;21(1):79–85. doi: https://doi.org/10.1097/ACI.0000000000000708Wangberg H, Woessner K. Choice of biologics in asthma endotypes. Curr Opin Allergy Clin Immunol. 2021;21(1):79–85. doi: https://doi.org/10.1097/ACI.0000000000000708Katsaounou P, Buhl R, Brusselle G, et al. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respir Med. 2019;150:51–62. doi: https://doi.org/10.1016/J.RMED.2019.02.003Katsaounou P, Buhl R, Brusselle G, et al. Omalizumab as alternative to chronic use of oral corticosteroids in severe asthma. Respir Med. 2019;150:51–62. doi: https://doi.org/10.1016/J.RMED.2019.02.003Gon Y, Maruoka S, Mizumura K. Omalizumab and IgE in the Control of Severe Allergic Asthma. Front Pharmacol. 2022;13:839011. doi: https://doi.org/10.3389/FPHAR.2022.839011Gon Y, Maruoka S, Mizumura K. Omalizumab and IgE in the Control of Severe Allergic Asthma. Front Pharmacol. 2022;13:839011. doi: https://doi.org/10.3389/FPHAR.2022.839011Henriksen DP, Bodtger U, Sidenius K, et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma — a systematic review and meta-analysis. Eur Clin Respir J. 2018;5(1):1536097. doi: https://doi.org/10.1080/20018525.2018.1536097Henriksen DP, Bodtger U, Sidenius K, et al. Efficacy, adverse events, and inter-drug comparison of mepolizumab and reslizumab anti-IL-5 treatments of severe asthma — a systematic review and meta-analysis. Eur Clin Respir J. 2018;5(1):1536097. doi: https://doi.org/10.1080/20018525.2018.1536097Flood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199–204. doi: https://doi.org/10.1164/RCCM.200208-789OCFlood-Page PT, Menzies-Gow AN, Kay AB, Robinson DS. Eosinophil’s role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am J Respir Crit Care Med. 2003;167(2):199–204. doi: https://doi.org/10.1164/RCCM.200208-789OCGarrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2004;113(1):115–119. doi: https://doi.org/10.1016/j.jaci.2003.10.049Garrett JK, Jameson SC, Thomson B, et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J Allergy Clin Immunol. 2004;113(1):115–119. doi: https://doi.org/10.1016/j.jaci.2003.10.049Egan RW, Athwal D, Bodmer MW, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999;49(9):779–790. doi: https://doi.org/10.1055/S-0031-1300502Egan RW, Athwal D, Bodmer MW, et al. Effect of Sch 55700, a humanized monoclonal antibody to human interleukin-5, on eosinophilic responses and bronchial hyperreactivity. Arzneimittelforschung. 1999;49(9):779–790. doi: https://doi.org/10.1055/S-0031-1300502Castro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132. doi: https://doi.org/10.1164/RCCM.201103-0396OCCastro M, Mathur S, Hargreave F, et al. Reslizumab for poorly controlled, eosinophilic asthma: a randomized, placebo-controlled study. Am J Respir Crit Care Med. 2011;184(10):1125–1132. doi: https://doi.org/10.1164/RCCM.201103-0396OCCastro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi: https://doi.org/10.1016/S2213-2600(15)00042-9Castro M, Zangrilli J, Wechsler ME, et al. Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials. Lancet Respir Med. 2015;3(5):355–366. doi: https://doi.org/10.1016/S2213-2600(15)00042-9Koike M, Nakamura K, Furuya A, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum Antibodies. 2009;18(1–2):17–27. doi: https://doi.org/10.3233/HAB-2009-0198Koike M, Nakamura K, Furuya A, et al. Establishment of humanized anti-interleukin-5 receptor alpha chain monoclonal antibodies having a potent neutralizing activity. Hum Antibodies. 2009;18(1–2):17–27. doi: https://doi.org/10.3233/HAB-2009-0198Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized antiIL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344– 1353.e2. doi: https://doi.org/10.1016/J.JACI.2010.04.004Kolbeck R, Kozhich A, Koike M, et al. MEDI-563, a humanized antiIL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin Immunol. 2010;125(6):1344– 1353.e2. doi: https://doi.org/10.1016/J.JACI.2010.04.004Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638– 1650. doi: https://doi.org/10.1016/S0140-6736(19)31881-1Bachert C, Han JK, Desrosiers M, et al. Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet. 2019;394(10209):1638– 1650. doi: https://doi.org/10.1016/S0140-6736(19)31881-1Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. doi: https://doi.org/10.1016/J.JACI.2018.08.022Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143(1):155–172. doi: https://doi.org/10.1016/J.JACI.2018.08.022Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. New Eng J Med. 2021;384(19):1800–1809. doi: https://doi.org/10.1056/NEJMOA2034975Menzies-Gow A, Corren J, Bourdin A, et al. Tezepelumab in Adults and Adolescents with Severe, Uncontrolled Asthma. New Eng J Med. 2021;384(19):1800–1809. doi: https://doi.org/10.1056/NEJMOA2034975Chen S, Tran TN, Cook W, et al. Clinical outcomes and emergency health care utilization in patients with severe asthma who continued, switched, or stopped biologic therapy: results from the CLEAR STUDY. Chest. 2022;162(4):A23–A27. doi: https://doi.org/10.1016/j.chest.2022.08.019Chen S, Tran TN, Cook W, et al. Clinical outcomes and emergency health care utilization in patients with severe asthma who continued, switched, or stopped biologic therapy: results from the CLEAR STUDY. Chest. 2022;162(4):A23–A27. doi: https://doi.org/10.1016/j.chest.2022.08.019Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014;133(3):921–923. doi: https://doi.org/10.1016/J.JACI.2013.11.026Haldar P, Brightling CE, Singapuri A, et al. Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis. J Allergy Clin Immunol. 2014;133(3):921–923. doi: https://doi.org/10.1016/J.JACI.2013.11.026Undela K, Goldsmith L, Kew KM, Ferrara G. Macrolides versus placebo for chronic asthma. Cochrane Database Syst Rev. 2021;11(11):CD002997. doi: https://doi.org/10.1002/14651858.CD002997.pub5Undela K, Goldsmith L, Kew KM, Ferrara G. Macrolides versus placebo for chronic asthma. Cochrane Database Syst Rev. 2021;11(11):CD002997. doi: https://doi.org/10.1002/14651858.CD002997.pub5Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of macrolides-A systematic review of the underlying mechanisms. Front Immunol. 2018;9:32. doi: https://doi.org/10.3389/FIMMU.2018.00302Zimmermann P, Ziesenitz VC, Curtis N, Ritz N. The immunomodulatory effects of macrolides-A systematic review of the underlying mechanisms. Front Immunol. 2018;9:32. doi: https://doi.org/10.3389/FIMMU.2018.00302Hiles SA, McDonald VM, Guilhermino M, et al. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data metaanalysis. Eur Respir J. 2019;54(5):1901381. doi: https://doi.org/10.1183/13993003.01381-2019Hiles SA, McDonald VM, Guilhermino M, et al. Does maintenance azithromycin reduce asthma exacerbations? An individual participant data metaanalysis. Eur Respir J. 2019;54(5):1901381. doi: https://doi.org/10.1183/13993003.01381-2019Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668. doi: https://doi.org/10.1016/S0140-6736(17)31281-3Gibson PG, Yang IA, Upham JW, et al. Effect of azithromycin on asthma exacerbations and quality of life in adults with persistent uncontrolled asthma (AMAZES): a randomised, double-blind, placebo-controlled trial. Lancet. 2017;390(10095):659–668. doi: https://doi.org/10.1016/S0140-6736(17)31281-3Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–329. doi: https://doi.org/10.1136/thoraxjnl-2012-202698Brusselle GG, Vanderstichele C, Jordens P, et al. Azithromycin for prevention of exacerbations in severe asthma (AZISAST): A multicentre randomised double-blind placebo-controlled trial. Thorax. 2013;68(4):322–329. doi: https://doi.org/10.1136/thoraxjnl-2012-202698Sadeghdoust M, Mirsadraee M, Aligolighasemabadi F, et al. Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial. Respir Med. 2021;185:106494. doi: https://doi.org/10.1016/J.RMED.2021.106494Sadeghdoust M, Mirsadraee M, Aligolighasemabadi F, et al. Effect of azithromycin on bronchial wall thickness in severe persistent asthma: A double-blind placebo-controlled randomized clinical trial. Respir Med. 2021;185:106494. doi: https://doi.org/10.1016/J.RMED.2021.106494Nievas IFF, Anand KJS. Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit. J Pediatr Pharmacol Ther. 2013;18(2):88–104. doi: https://doi.org/10.5863/1551-6776-18.2.88Nievas IFF, Anand KJS. Severe acute asthma exacerbation in children: a stepwise approach for escalating therapy in a pediatric intensive care unit. J Pediatr Pharmacol Ther. 2013;18(2):88–104. doi: https://doi.org/10.5863/1551-6776-18.2.88Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013;2013(9):CD000052. doi: https://doi.org/10.1002/14651858.CD000052.pub3Cates CJ, Welsh EJ, Rowe BH. Holding chambers (spacers) versus nebulisers for beta-agonist treatment of acute asthma. Cochrane Database Syst Rev. 2013;2013(9):CD000052. doi: https://doi.org/10.1002/14651858.CD000052.pub3Haney S, Hancox RJ. Overcoming beta-agonist tolerance: High dose salbutamol and ipratropium bromide. Two randomised controlled trials. Respir Res. 2007;8(1):1–7. doi: https://doi.org/10.1186/1465-9921-8-19/FIGURES/2_557Haney S, Hancox RJ. Overcoming beta-agonist tolerance: High dose salbutamol and ipratropium bromide. Two randomised controlled trials. Respir Res. 2007;8(1):1–7. doi: https://doi.org/10.1186/1465-9921-8-19/FIGURES/2_557Авдеев С.Н., Жестков А.В., Лещенко И.В. и др. Небулизированный будесонид при тяжелом обострении бронхиальной астмы: сравнение с системными стероидами. Мультицентровое рандомизированное контролируемое исследование // Пульмонология. — 2006. — № 4. — С. 58–67. — doi: https://doi.org/10.18093/0869-0189-2006-4-58-67Avdeev S, Zhestkov A, Leshenko I, et al. Nebulized budesonide in acute severe asthma: comparison with systemic corticosteroids. Multicenre randomized controlled trial. Pulmonologiya. 2006;(4):58–67. (In Russ). doi: https://doi.org/10.18093/0869-0189-2006-4-58-67Бегунов А.В., Зарубина Е.Г., Бетанели Т.Ш. Небулайзерная терапия суспензией Пульмикорта при тяжелой бронхиальной астме // Атмосфера. Пульмонология и аллергология. — 2003. — № 4. — С. 51–52.Begunov AV, Zarubina EG, Betaneli TSh. Nebulaizernaya terapiya suspenziei Pul’mikorta pri tyazheloi bronkhial’noi astme. Atmosfera. Pul’monologiya i allergologiya. 2023;(4):51–52. (In Russ).Edmonds ML, Milan SJ, Camargo CA, et al. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2012;12(12):CD002308. doi: https://doi.org/10.1002/14651858.CD002308.pub2Edmonds ML, Milan SJ, Camargo CA, et al. Early use of inhaled corticosteroids in the emergency department treatment of acute asthma. Cochrane Database Syst Rev. 2012;12(12):CD002308. doi: https://doi.org/10.1002/14651858.CD002308.pub2Edmonds ML, Milan SJ, Brenner BE, et al. Inhaled steroids for acute asthma following emergency department discharge. Cochrane Database Syst Rev. 2012;12(12):CD002316. doi: https://doi.org/10.1002/14651858.CD002316.pub2Edmonds ML, Milan SJ, Brenner BE, et al. Inhaled steroids for acute asthma following emergency department discharge. Cochrane Database Syst Rev. 2012;12(12):CD002316. doi: https://doi.org/10.1002/14651858.CD002316.pub2Volovitz B. Inhaled budesonide in the management of acute worsenings and exacerbations of asthma: A review of the evidence. Respir Med. 2007;101(4):685–695. doi: https://doi.org/10.1016/j.rmed.2006.10.009Volovitz B. Inhaled budesonide in the management of acute worsenings and exacerbations of asthma: A review of the evidence. Respir Med. 2007;101(4):685–695. doi: https://doi.org/10.1016/j.rmed.2006.10.009Arulparithi CS, Babu TA, Ravichandran C, et al. Efficacy of Nebulised Budesonide versus Oral Prednisolone in Acute Severe Asthma. Indian J Pediatr. 2015;82(4):328–332. doi: https://doi.org/10.1007/s12098-014-1498-0Arulparithi CS, Babu TA, Ravichandran C, et al. Efficacy of Nebulised Budesonide versus Oral Prednisolone in Acute Severe Asthma. Indian J Pediatr. 2015;82(4):328–332. doi: https://doi.org/10.1007/s12098-014-1498-0Chen AH, Zeng GQ, Chen RC, et al. Effects of nebulized highdose budesonide on moderate-to-severe acute exacerbation of asthma in children: a randomized, double-blind, placebo-controlled study. Respirology. 2013;18(Suppl 3):47–52. doi: https://doi.org/10.1111/RESP.12168Chen AH, Zeng GQ, Chen RC, et al. Effects of nebulized highdose budesonide on moderate-to-severe acute exacerbation of asthma in children: a randomized, double-blind, placebo-controlled study. Respirology. 2013;18(Suppl 3):47–52. doi: https://doi.org/10.1111/RESP.12168Ediger D, Coşkun F, Kunt Uzaslan E, et al. Clinical effectiveness of nebulised budesonide in the treatment of acute asthma attacks. Tuberk Toraks. 2006;54(2):128–136.Ediger D, Coşkun F, Kunt Uzaslan E, et al. Clinical effectiveness of nebulised budesonide in the treatment of acute asthma attacks. Tuberk Toraks. 2006;54(2):128–136.Murphy KR, Hong JG, Wandalsen G, et al. Nebulized Inhaled Corticosteroids in Asthma Treatment in Children 5 Years or Younger: A Systematic Review and Global Expert Analysis. J Allergy Clinl Immunol Pract. 2020;8(6):1815–1827. doi: https://doi.org/10.1016/J.JAIP.2020.01.042Murphy KR, Hong JG, Wandalsen G, et al. Nebulized Inhaled Corticosteroids in Asthma Treatment in Children 5 Years or Younger: A Systematic Review and Global Expert Analysis. J Allergy Clinl Immunol Pract. 2020;8(6):1815–1827. doi: https://doi.org/10.1016/J.JAIP.2020.01.042Volovitz B, Nussinovitch M, Finkelstein Y, et al. Effectiveness of inhaled corticosteroids in controlling acute asthma exacerbations in children at home. Clin Pediatr. 2001;40(2):79–86. doi: https://doi.org/10.1177/000992280104000203Volovitz B, Nussinovitch M, Finkelstein Y, et al. Effectiveness of inhaled corticosteroids in controlling acute asthma exacerbations in children at home. Clin Pediatr. 2001;40(2):79–86. doi: https://doi.org/10.1177/000992280104000203Higenbottam TW, Britton J, Lawrence D, et al. Comparison of Nebulised Budesonide and Prednisolone in Severe Asthma Exacerbation in Adults. BioDrugs. 2000;14(4):247–254. doi: https://doi.org/10.2165/00063030-200014040-00004Higenbottam TW, Britton J, Lawrence D, et al. Comparison of Nebulised Budesonide and Prednisolone in Severe Asthma Exacerbation in Adults. BioDrugs. 2000;14(4):247–254. doi: https://doi.org/10.2165/00063030-200014040-00004Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002;165(5):698–703. doi: https://doi.org/10.1164/AJRCCM.165.5.2109093Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir Crit Care Med. 2002;165(5):698–703. doi: https://doi.org/10.1164/AJRCCM.165.5.2109093Ververeli K, Chipps B. Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma. Ann Allergy Asthma Immunol. 2004;92(5):512–522. doi: https://doi.org/10.1016/S1081-1206(10)61758-9Ververeli K, Chipps B. Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma. Ann Allergy Asthma Immunol. 2004;92(5):512–522. doi: https://doi.org/10.1016/S1081-1206(10)61758-9Edmonds ML, Camargo CA, Brenner BE, Rowe BH. Replacement of oral corticosteroids with inhaled corticosteroids in the treatment of acute asthma following emergency department discharge: A meta-analysis. Chest. 2002;121(6):1798–1805. doi: https://doi.org/10.1378/chest.121.6.1798Edmonds ML, Camargo CA, Brenner BE, Rowe BH. Replacement of oral corticosteroids with inhaled corticosteroids in the treatment of acute asthma following emergency department discharge: A meta-analysis. Chest. 2002;121(6):1798–1805. doi: https://doi.org/10.1378/chest.121.6.1798Matthews EE, Curtis PD, McLain BI, et al. Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr. 1999;88(8):841–843. doi: https://doi.org/10.1080/08035259950168757Matthews EE, Curtis PD, McLain BI, et al. Nebulized budesonide versus oral steroid in severe exacerbations of childhood asthma. Acta Paediatr. 1999;88(8):841–843. doi: https://doi.org/10.1080/08035259950168757Devidayal, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr. 1999;88(8):835–840. doi: https://doi.org/10.1080/08035259950168748Devidayal, Singhi S, Kumar L, Jayshree M. Efficacy of nebulized budesonide compared to oral prednisolone in acute bronchial asthma. Acta Paediatr. 1999;88(8):835–840. doi: https://doi.org/10.1080/08035259950168748Sano F, Cortez GK, Solé D, Naspitz CK. Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone. J Allergy Clin Immunol. 2000;105(4):699–703. doi: https://doi.org/10.1067/MAI.2000.104784Sano F, Cortez GK, Solé D, Naspitz CK. Inhaled budesonide for the treatment of acute wheezing and dyspnea in children up to 24 months old receiving intravenous hydrocortisone. J Allergy Clin Immunol. 2000;105(4):699–703. doi: https://doi.org/10.1067/MAI.2000.104784Sharma S, Harish R, Dutt N, Digra KK. To evaluate the efficacy of nebulized budesonide compared to oral prednisolone in the management of moderate exacerbation of acute asthma. Int J Contemp Pediatrics. 2017;4(4):1278–1283. doi: https://doi.org/10.18203/2349-3291.IJCP20172542Sharma S, Harish R, Dutt N, Digra KK. To evaluate the efficacy of nebulized budesonide compared to oral prednisolone in the management of moderate exacerbation of acute asthma. Int J Contemp Pediatrics. 2017;4(4):1278–1283. doi: https://doi.org/10.18203/2349-3291.IJCP20172542Fitzgerald JM, Shragge D, Haddon J, et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can Respir J. 2000;7(1): 61–67. doi: https://doi.org/10.1155/2000/587957Fitzgerald JM, Shragge D, Haddon J, et al. A randomized, controlled trial of high dose, inhaled budesonide versus oral prednisone in patients discharged from the emergency department following an acute asthma exacerbation. Can Respir J. 2000;7(1): 61–67. doi: https://doi.org/10.1155/2000/587957Nana A, Youngchaiyud P, Charoenratanakul S, et al. High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack. J Asthma. 1998;35(8):647–655. doi: https://doi.org/10.3109/02770909809048967Nana A, Youngchaiyud P, Charoenratanakul S, et al. High-dose inhaled budesonide may substitute for oral therapy after an acute asthma attack. J Asthma. 1998;35(8):647–655. doi: https://doi.org/10.3109/02770909809048967Rowe BH, Bota GW, Fabris L, et al. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA. 1999;281(22):2119–2126. doi: https://doi.org/10.1001/JAMA.281.22.2119Rowe BH, Bota GW, Fabris L, et al. Inhaled budesonide in addition to oral corticosteroids to prevent asthma relapse following discharge from the emergency department: a randomized controlled trial. JAMA. 1999;281(22):2119–2126. doi: https://doi.org/10.1001/JAMA.281.22.2119Manser R, Reid D, Abramson MJ. Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev. 2001;(1):CD001740. doi: https://doi.org/10.1002/14651858.CD001740Manser R, Reid D, Abramson MJ. Corticosteroids for acute severe asthma in hospitalised patients. Cochrane Database Syst Rev. 2001;(1):CD001740. doi: https://doi.org/10.1002/14651858.CD001740Ganaie MB, Munavvar M, Gordon M, et al. Patient- and parent-initiated oral steroids for asthma exacerbations. Cochrane Database Syst Rev. 2016;12(12):CD012195. doi: https://doi.org/10.1002/14651858.CD012195.PUB2Ganaie MB, Munavvar M, Gordon M, et al. Patient- and parent-initiated oral steroids for asthma exacerbations. Cochrane Database Syst Rev. 2016;12(12):CD012195. doi: https://doi.org/10.1002/14651858.CD012195.PUB2Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. doi: https://doi.org/10.1183/13993003.00703-2018Volmer T, Effenberger T, Trautner C, Buhl R. Consequences of long-term oral corticosteroid therapy and its side-effects in severe asthma in adults: a focused review of the impact data in the literature. Eur Respir J. 2018;52(4):1800703. doi: https://doi.org/10.1183/13993003.00703-2018Del Pozo V, Bobolea I, Rial MJ, et al. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases. Front Immunol. 2023;14:1310211. doi: https://doi.org/10.3389/fimmu.2023.1310211Del Pozo V, Bobolea I, Rial MJ, et al. Expert consensus on the use of systemic glucocorticoids for managing eosinophil-related diseases. Front Immunol. 2023;14:1310211. doi: https://doi.org/10.3389/fimmu.2023.1310211Hew M, Chung KF. Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology. Int Med J. 2010;40(5):323– 334. doi: https://doi.org/10.1111/J.1445-5994.2010.02192.XHew M, Chung KF. Corticosteroid insensitivity in severe asthma: significance, mechanisms and aetiology. Int Med J. 2010;40(5):323– 334. doi: https://doi.org/10.1111/J.1445-5994.2010.02192.XChang AB, Clark R, Sloots TP, et al. A 5- versus 3-day course of oral corticosteroids for children with asthma exacerbations who are not hospitalised: a randomised controlled trial. Med J Aust. 2008;189(6):306–310. doi: https://doi.org/10.5694/J.1326-5377.2008.TB02046.XChang AB, Clark R, Sloots TP, et al. A 5- versus 3-day course of oral corticosteroids for children with asthma exacerbations who are not hospitalised: a randomised controlled trial. Med J Aust. 2008;189(6):306–310. doi: https://doi.org/10.5694/J.1326-5377.2008.TB02046.XHasegawa T, Ishihara K, Takakura S, et al. Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. Int Med. 2000;39(10):794–797. doi: https://doi.org/10.2169/INTERNALMEDICINE.39.794Hasegawa T, Ishihara K, Takakura S, et al. Duration of systemic corticosteroids in the treatment of asthma exacerbation; a randomized study. Int Med. 2000;39(10):794–797. doi: https://doi.org/10.2169/INTERNALMEDICINE.39.794Jones AM, Munavvar M, Vail A, et al. Prospective, placebocontrolled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir Med. 2002;96(11):950–954. doi: https://doi.org/10.1053/RMED.2002.1369Jones AM, Munavvar M, Vail A, et al. Prospective, placebocontrolled trial of 5 vs 10 days of oral prednisolone in acute adult asthma. Respir Med. 2002;96(11):950–954. doi: https://doi.org/10.1053/RMED.2002.1369Knightly R, Milan SJ, Hughes R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev. 2017;11(11):CD003898. doi: https://doi.org/10.1002/14651858.CD003898.PUB6Knightly R, Milan SJ, Hughes R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev. 2017;11(11):CD003898. doi: https://doi.org/10.1002/14651858.CD003898.PUB6Kew KM, Kirtchuk L, Michell CI. Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database Syst Rev. 2014;2014(5):CD010909. doi: https://doi.org/10.1002/14651858.CD010909.pub2Kew KM, Kirtchuk L, Michell CI. Intravenous magnesium sulfate for treating adults with acute asthma in the emergency department. Cochrane Database Syst Rev. 2014;2014(5):CD010909. doi: https://doi.org/10.1002/14651858.CD010909.pub2Craig SS, Dalziel SR, Powell CVE, et al. Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2020;8(8):CD012977. doi: https://doi.org/10.1002/14651858.CD012977.pub2Craig SS, Dalziel SR, Powell CVE, et al. Interventions for escalation of therapy for acute exacerbations of asthma in children: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2020;8(8):CD012977. doi: https://doi.org/10.1002/14651858.CD012977.pub2Blitz M, Blitz S, Beasely R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev. 2005;(3):CD003898. doi: https://doi.org/10.1002/14651858.cd003898.pub3Blitz M, Blitz S, Beasely R, et al. Inhaled magnesium sulfate in the treatment of acute asthma. Cochrane Database Syst Rev. 2005;(3):CD003898. doi: https://doi.org/10.1002/14651858.cd003898.pub3Rovsing AH, Savran O, Ulrik CS. Magnesium sulfate treatment for acute severe asthma in adults-a systematic review and meta-analysis. Front Allergy. 2023;4:1211949. doi: https://doi.org/10.3389/falgy.2023.1211949Rovsing AH, Savran O, Ulrik CS. Magnesium sulfate treatment for acute severe asthma in adults-a systematic review and meta-analysis. Front Allergy. 2023;4:1211949. doi: https://doi.org/10.3389/falgy.2023.1211949Goodacre S, Cohen J, Bradburn M, et al. Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): A double-blind, randomised controlled trial. Lancet Respir Med. 2013;1(4):293–300. doi: https://doi.org/10.1016/S2213-2600(13)70070-5Goodacre S, Cohen J, Bradburn M, et al. Intravenous or nebulised magnesium sulphate versus standard therapy for severe acute asthma (3Mg trial): A double-blind, randomised controlled trial. Lancet Respir Med. 2013;1(4):293–300. doi: https://doi.org/10.1016/S2213-2600(13)70070-5Craig SS, Dalziel SR, Powell CVE, et al. Interventions for escalation of therapy for acute exacerbations of asthma in children: An overview of Cochrane reviews. Paediatr Respir Rev. 2021;38: 63–65. doi: https://doi.org/10.1016/J.PRRV.2020.08.006Craig SS, Dalziel SR, Powell CVE, et al. Interventions for escalation of therapy for acute exacerbations of asthma in children: An overview of Cochrane reviews. Paediatr Respir Rev. 2021;38: 63–65. doi: https://doi.org/10.1016/J.PRRV.2020.08.006Gondal AZ, Zulfiqar H. Aminophylline. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.Gondal AZ, Zulfiqar H. Aminophylline. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025.Gray CS, Xu Y, Babl FE, et al. International perspective on research priorities and outcome measures of importance in the care of children with acute exacerbations of asthma: a qualitative interview study. BMJ Open Respir Res. 2023;10(1):e001502. doi: https://doi.org/10.1136/BMJRESP-2022-001502Gray CS, Xu Y, Babl FE, et al. International perspective on research priorities and outcome measures of importance in the care of children with acute exacerbations of asthma: a qualitative interview study. BMJ Open Respir Res. 2023;10(1):e001502. doi: https://doi.org/10.1136/BMJRESP-2022-001502Craig S, Powell CVE, Nixon GM, et al. Treatment patterns and frequency of key outcomes in acute severe asthma in children: A Paediatric Research in Emergency Departments International Collaborative (PREDICT) multicentre cohort study. BMJ Open Respir Res. 2022;9(1):e001137. doi: https://doi.org/10.1136/BMJRESP-2021-001137Craig S, Powell CVE, Nixon GM, et al. Treatment patterns and frequency of key outcomes in acute severe asthma in children: A Paediatric Research in Emergency Departments International Collaborative (PREDICT) multicentre cohort study. BMJ Open Respir Res. 2022;9(1):e001137. doi: https://doi.org/10.1136/BMJRESP-2021-001137Koldeweij C, Appelbaum N, Gonzalvez CR, et al. Mind the gap: Mapping variation between national and local clinical practice guidelines for acute paediatric asthma from the United Kingdom and the Netherlands. PLoS One. 2022;17(5):e0267445. doi: https://doi.org/10.1371/JOURNAL.PONE.0267445Koldeweij C, Appelbaum N, Gonzalvez CR, et al. Mind the gap: Mapping variation between national and local clinical practice guidelines for acute paediatric asthma from the United Kingdom and the Netherlands. PLoS One. 2022;17(5):e0267445. doi: https://doi.org/10.1371/JOURNAL.PONE.0267445Шайтор В.М. Скорая и неотложная медицинская помощь детям на догоспитальном этапе: краткое руководство для врачей. — СПб.: ИнформМед; 2013. — С. 120–125.Shaitor VM. Skoraya i neotlozhnaya meditsinskaya pomoshch’ detyam na dogospital’nom etape: A quick guide for doctors. St. Petersburg: InformMed; 2013. pp. 120–125. (In Russ).Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Nat Acad Sci U S A. 2002;99(13):8921–8926. doi: https://doi.org/10.1073/PNAS.132556899Ito K, Lim S, Caramori G, et al. A molecular mechanism of action of theophylline: Induction of histone deacetylase activity to decrease inflammatory gene expression. Proc Nat Acad Sci U S A. 2002;99(13):8921–8926. doi: https://doi.org/10.1073/PNAS.132556899Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax. 2009;64(5):424–429. doi: https://doi.org/10.1136/THX.2008.103432Cosio BG, Iglesias A, Rios A, et al. Low-dose theophylline enhances the anti-inflammatory effects of steroids during exacerbations of COPD. Thorax. 2009;64(5):424–429. doi: https://doi.org/10.1136/THX.2008.103432To Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3- kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(7):897–904. doi: https://doi.org/10.1164/RCCM.200906-0937OCTo Y, Ito K, Kizawa Y, et al. Targeting phosphoinositide-3- kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2010;182(7):897–904. doi: https://doi.org/10.1164/RCCM.200906-0937OCMitra AA, Bassler D, Watts K, et al. Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database Syst Rev. 2005;2005(2):CD001276. doi: https://doi.org/10.1002/14651858.cd001276.pub2Mitra AA, Bassler D, Watts K, et al. Intravenous aminophylline for acute severe asthma in children over two years receiving inhaled bronchodilators. Cochrane Database Syst Rev. 2005;2005(2):CD001276. doi: https://doi.org/10.1002/14651858.cd001276.pub2Rahmania M, Olivianto E. Intravenous aminophylline treatment for severe asthma exacerbation in a toddler: an evidence-based case report. PSJ. 2022;3(2):30–36. doi: https://doi.org/10.51559/pedscij.v3i2.39Rahmania M, Olivianto E. Intravenous aminophylline treatment for severe asthma exacerbation in a toddler: an evidence-based case report. PSJ. 2022;3(2):30–36. doi: https://doi.org/10.51559/pedscij.v3i2.39Eid NS, O’Hagan A, Bickel S, et al. Anti-inflammatory dosing of theophylline in the treatment of status asthmaticus in children. J Asthma Allergy. 2016;9:183–189. doi: https://doi.org/10.2147/JAA.S113747Eid NS, O’Hagan A, Bickel S, et al. Anti-inflammatory dosing of theophylline in the treatment of status asthmaticus in children. J Asthma Allergy. 2016;9:183–189. doi: https://doi.org/10.2147/JAA.S113747Perrin K, Wijesinghe M, Healy B, et al. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax. 2011;66(11):937–941. doi: https://doi.org/10.1136/THX.2010.155259Perrin K, Wijesinghe M, Healy B, et al. Randomised controlled trial of high concentration versus titrated oxygen therapy in severe exacerbations of asthma. Thorax. 2011;66(11):937–941. doi: https://doi.org/10.1136/THX.2010.155259Rodrigo GJ, Verde MR, Peregalli V, Rodrigo C. Effects of shortterm 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest. 2003;124(4): 1312–1317. doi: https://doi.org/10.1378/CHEST.124.4.1312Rodrigo GJ, Verde MR, Peregalli V, Rodrigo C. Effects of shortterm 28% and 100% oxygen on PaCO2 and peak expiratory flow rate in acute asthma: a randomized trial. Chest. 2003;124(4): 1312–1317. doi: https://doi.org/10.1378/CHEST.124.4.1312Gupta DA. A prospective randomized controlled trial on the efficacy of noninvasive ventilation in severe acute asthma. Respir Care. 2010;55(5):536–543Gupta DA. A prospective randomized controlled trial on the efficacy of noninvasive ventilation in severe acute asthma. Respir Care. 2010;55(5):536–543Agarwal R, Reddy C, Aggarwal AN, Gupta D. Is there a role for noninvasive ventilation in acute respiratory distress syndrome? A meta-analysis. Respir Med. 2006;100(12):2235–2238. doi: https://doi.org/10.1016/j.rmed.2006.03.018Agarwal R, Reddy C, Aggarwal AN, Gupta D. Is there a role for noninvasive ventilation in acute respiratory distress syndrome? A meta-analysis. Respir Med. 2006;100(12):2235–2238. doi: https://doi.org/10.1016/j.rmed.2006.03.018Авдеев С.Н. Респираторная поддержка при астматическом статусе // Бронхиальная астма у взрослых: клинические рекомендации / под ред. А.Г. Чучалина. — М.: Атмосфера; 2002. — С. 130–155.Avdeev SN. Respiratornaya podderzhka pri astmaticheskom statuse. In: Bronkhial’naya astma u vzroslykh: Clinical guidelines. Chuchalin AG, ed. Moscow: Atmosfera; 2002. pp. 130–155. (In Russ).Kuyper LM, Paré PD, Hogg JC, et al. Characterization of airway plugging in fatal asthma. Am J Med. 2003;115(1):6–11. doi: https://doi.org/10.1016/S0002-9343(03)00241-9Kuyper LM, Paré PD, Hogg JC, et al. Characterization of airway plugging in fatal asthma. Am J Med. 2003;115(1):6–11. doi: https://doi.org/10.1016/S0002-9343(03)00241-9Inwald D, Roland M, Kuitert L, et al. (Oxygen treatment for acute severe asthma. Brit Med J. 2001;323(7304):98–100. doi: https://doi.org/10.1136/BMJ.323.7304.98Inwald D, Roland M, Kuitert L, et al. (Oxygen treatment for acute severe asthma. Brit Med J. 2001;323(7304):98–100. doi: https://doi.org/10.1136/BMJ.323.7304.98Pollart SM, Compton RM, Elward KS. Management of Acute Asthma Exacerbations. Am Fam Physician. 2011;84(1):40–47. doi: https://www.aafp.org/pubs/afp/issues/2011/0701/p40.htmlPollart SM, Compton RM, Elward KS. Management of Acute Asthma Exacerbations. Am Fam Physician. 2011;84(1):40–47. doi: https://www.aafp.org/pubs/afp/issues/2011/0701/p40.htmlSiemieniuk RAC, Chu DK, Kim LHY, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ. 2018;363:k4169. doi: https://doi.org/10.1136/BMJ.K4169Siemieniuk RAC, Chu DK, Kim LHY, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ. 2018;363:k4169. doi: https://doi.org/10.1136/BMJ.K4169Patel B, Khine H, Shah A, et al. Randomized clinical trial of high concentration versus titrated oxygen use in pediatric asthma. Pediatr Pulmonol. 2019;54(7):970–976. doi: https://doi.org/10.1002/PPUL.24329Patel B, Khine H, Shah A, et al. Randomized clinical trial of high concentration versus titrated oxygen use in pediatric asthma. Pediatr Pulmonol. 2019;54(7):970–976. doi: https://doi.org/10.1002/PPUL.24329Carroll CL, Smith SR, Collins MS, et al. Endotracheal intubation and pediatric status asthmaticus: site of original care affects treatment. Pediatr Crit Care Med. 2007;8(2):91–95. doi: https://doi.org/10.1097/01.PCC.0000257115.02573.FCCarroll CL, Smith SR, Collins MS, et al. Endotracheal intubation and pediatric status asthmaticus: site of original care affects treatment. Pediatr Crit Care Med. 2007;8(2):91–95. doi: https://doi.org/10.1097/01.PCC.0000257115.02573.FCZimmerman JL, Dellinger RP, Shah AN, Taylor RW. Endotracheal intubation and mechanical ventilation in severe asthma. Crit Care Med. 1993;21(11):1727–1730. doi: https://doi.org/10.1097/00003246-199311000-00023Zimmerman JL, Dellinger RP, Shah AN, Taylor RW. Endotracheal intubation and mechanical ventilation in severe asthma. Crit Care Med. 1993;21(11):1727–1730. doi: https://doi.org/10.1097/00003246-199311000-00023Kilburn SA, Lasserson TJ, McKean MC. Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev. 2003;2001(1):CD002989. doi: https://doi.org/10.1002/14651858.CD002989Kilburn SA, Lasserson TJ, McKean MC. Pet allergen control measures for allergic asthma in children and adults. Cochrane Database Syst Rev. 2003;2001(1):CD002989. doi: https://doi.org/10.1002/14651858.CD002989Zuiani C, Custovic A. Update on House Dust Mite Allergen Avoidance Measures for Asthma. Curr Allergy Asthma Rep. 2020;20(9):50. doi: https://doi.org/10.1007/S11882-020-00948-YZuiani C, Custovic A. Update on House Dust Mite Allergen Avoidance Measures for Asthma. Curr Allergy Asthma Rep. 2020;20(9):50. doi: https://doi.org/10.1007/S11882-020-00948-YMarks GB. House dust mite exposure as a risk factor for asthma: benefits of avoidance. Allergy. 1998;53(48 Suppl):108–114. doi: https://doi.org/10.1111/j.1398-9995.1998.tb05010.xMarks GB. House dust mite exposure as a risk factor for asthma: benefits of avoidance. Allergy. 1998;53(48 Suppl):108–114. doi: https://doi.org/10.1111/j.1398-9995.1998.tb05010.xCustovic A, Murray CS, Simpson A. Dust-mite inducing asthma: what advice can be given to patients? Expert Rev Respir Med. 2019;13(10):929–936. doi: https://doi.org/10.1080/17476348.2019.1651647Custovic A, Murray CS, Simpson A. Dust-mite inducing asthma: what advice can be given to patients? Expert Rev Respir Med. 2019;13(10):929–936. doi: https://doi.org/10.1080/17476348.2019.1651647Custovic A, de Moira AP, Murray CS, Simpson A. Environmental influences on childhood asthma: Allergens. Pediatr Allergy Immunol. 2023;34(2):e13915. doi: https://doi.org/10.1111/pai.13915Custovic A, de Moira AP, Murray CS, Simpson A. Environmental influences on childhood asthma: Allergens. Pediatr Allergy Immunol. 2023;34(2):e13915. doi: https://doi.org/10.1111/pai.13915Федеральные клинические рекомендации по проведению аллерген-специфической иммунотерапии / Российская ассоциация аллергологов и клинических иммунологов. — М.; 2013. — 14 с. Доступно по: https://raaci.ru/education/clinic_recomendations/103.html. Ссылка активна на 26.06.2025.Federalnye klinicheskie rekomendatsii po provedeniyu allergen-spetsificheskoi immunoterapii. Russian Association of Allergologists and Clinical Immunologists. Moscow; 2013. 14 p. (In Russ). Доступно по: https://raaci.ru/education/clinic_recomendations/103.html. Ссылка активна на 26.06.2025.Zuberbier T, Bachert C, Bousquet PJ, et al. GA2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65(12):1525–1530. doi: https://doi.org/10.1111/J.1398-9995.2010.02474.XZuberbier T, Bachert C, Bousquet PJ, et al. GA2 LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy. 2010;65(12):1525–1530. doi: https://doi.org/10.1111/J.1398-9995.2010.02474.XAbramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;(8): CD001186. doi: https://doi.org/10.1002/14651858.CD001186.pub2Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;(8): CD001186. doi: https://doi.org/10.1002/14651858.CD001186.pub2Zheng C, Xu H, Huang S, Chen Z. Efficacy and safety of subcutaneous immunotherapy in asthmatic children allergic to house dust mite: a meta-analysis and systematic review. Front Pediatr. 2023;11:1137478. doi: https://doi.org/10.3389/fped.2023.1137478Zheng C, Xu H, Huang S, Chen Z. Efficacy and safety of subcutaneous immunotherapy in asthmatic children allergic to house dust mite: a meta-analysis and systematic review. Front Pediatr. 2023;11:1137478. doi: https://doi.org/10.3389/fped.2023.1137478Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6. doi: https://doi.org/10.1186/1939-4551-7-6Canonica GW, Cox L, Pawankar R, et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. World Allergy Organ J. 2014;7(1):6. doi: https://doi.org/10.1186/1939-4551-7-6Hoshino M, Akitsu K, Ohtawa J, Kubota K. Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis. J Allergy Clin Immunol Glob. 2024;3(2):100206. doi: https://doi.org/10.1016/J.JACIG.2024.100206Hoshino M, Akitsu K, Ohtawa J, Kubota K. Long-term efficacy of house dust mite sublingual immunotherapy on clinical and pulmonary function in patients with asthma and allergic rhinitis. J Allergy Clin Immunol Glob. 2024;3(2):100206. doi: https://doi.org/10.1016/J.JACIG.2024.100206Agache I, Lau S, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019;74(5):855–873. doi: https://doi.org/10.1111/ALL.13749Agache I, Lau S, Akdis CA, et al. EAACI Guidelines on Allergen Immunotherapy: House dust mite-driven allergic asthma. Allergy. 2019;74(5):855–873. doi: https://doi.org/10.1111/ALL.13749Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020;9(9):CD011293. doi: https://doi.org/10.1002/14651858.CD011293.pub3Fortescue R, Kew KM, Leung MST. Sublingual immunotherapy for asthma. Cochrane Database Syst Rev. 2020;9(9):CD011293. doi: https://doi.org/10.1002/14651858.CD011293.pub3Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial. JAMA. 2016;315(16): 1715–1725. doi: https://doi.org/10.1001/jama.2016.3964Virchow JC, Backer V, Kuna P, et al. Efficacy of a house dust mite sublingual allergen immunotherapy tablet in adults with allergic asthma: A randomized clinical trial. JAMA. 2016;315(16): 1715–1725. doi: https://doi.org/10.1001/jama.2016.3964Nakagome K, Nagata M. Allergen Immunotherapy in Asthma. Pathogens. 2021;10(11):1406. doi: https://doi.org/10.3390/pathogens10111406Nakagome K, Nagata M. Allergen Immunotherapy in Asthma. Pathogens. 2021;10(11):1406. doi: https://doi.org/10.3390/pathogens10111406Tanaka A, Tohda Y, Okamiya K, et al. Efficacy and Safety of HDM SLIT Tablet in Japanese Adults with Allergic Asthma. J Allergy Clinl Immunol Pract. 2020;8(2):710–720.e14. doi: https://doi.org/10.1016/J.JAIP.2019.09.002Tanaka A, Tohda Y, Okamiya K, et al. Efficacy and Safety of HDM SLIT Tablet in Japanese Adults with Allergic Asthma. J Allergy Clinl Immunol Pract. 2020;8(2):710–720.e14. doi: https://doi.org/10.1016/J.JAIP.2019.09.002Nishi K, Yoshimura C, Morita K, et al. Effectiveness of bronchial thermoplasty in patients with asthma exhibiting overweight/obesity and low quality of life. World Allergy Organ J. 2023;16(3):100756. doi: https://doi.org/10.1016/j.waojou.2023.100756Nishi K, Yoshimura C, Morita K, et al. Effectiveness of bronchial thermoplasty in patients with asthma exhibiting overweight/obesity and low quality of life. World Allergy Organ J. 2023;16(3):100756. doi: https://doi.org/10.1016/j.waojou.2023.100756Madsen H, Henriksen DP, Backer V, et al. Efficacy of bronchial thermoplasty in patients with severe asthma. J Asthma. 2021;58(2):216–222. doi: https://doi.org/10.1080/02770903.2019.1678636Madsen H, Henriksen DP, Backer V, et al. Efficacy of bronchial thermoplasty in patients with severe asthma. J Asthma. 2021;58(2):216–222. doi: https://doi.org/10.1080/02770903.2019.1678636Bonta PI, Chanez P, Annema JT, et al. Bronchial Thermoplasty in Severe Asthma: Best Practice Recommendations from an Expert Panel. Respiration. 2018;95(5):289–300. doi: https://doi.org/10.1159/000488291Bonta PI, Chanez P, Annema JT, et al. Bronchial Thermoplasty in Severe Asthma: Best Practice Recommendations from an Expert Panel. Respiration. 2018;95(5):289–300. doi: https://doi.org/10.1159/000488291Burn J, Sims AJ, Patrick H, et al. Efficacy and safety of bronchial thermoplasty in clinical practice: a prospective, longitudinal, cohort study using evidence from the UK Severe Asthma Registry. BMJ Open. 2019;9(6):e026742. doi: https://doi.org/10.1136/BMJOPEN-2018-026742Burn J, Sims AJ, Patrick H, et al. Efficacy and safety of bronchial thermoplasty in clinical practice: a prospective, longitudinal, cohort study using evidence from the UK Severe Asthma Registry. BMJ Open. 2019;9(6):e026742. doi: https://doi.org/10.1136/BMJOPEN-2018-026742Madan K, Mittal S, Suri TM, et al. Bronchial thermoplasty for severe asthma: A position statement of the Indian chest society. Lung India. 2020;37(1):86–96. doi: https://doi.org/10.4103/LUNGINDIA.LUNGINDIA_418_19Madan K, Mittal S, Suri TM, et al. Bronchial thermoplasty for severe asthma: A position statement of the Indian chest society. Lung India. 2020;37(1):86–96. doi: https://doi.org/10.4103/LUNGINDIA.LUNGINDIA_418_19Куклина Г.М., Сивокозов И.В., Макарьянц Н.Н., Шмелёв Е.И. Успешный опыт применения бронхиальной термопластики у пациентки с тяжелым течением бронхиальной астмы // Доктор.Ру. — 2020. — Т. 19. — № 11. — С. 38–41. — doi: https://doi.org/10.31550/1727-2378-2020-19-11-38-41Kuklina GM, Sivokozov IV, Makaryants NN, Shmelev EI. Successful Use of Bronchial Thermoplastics in a Female Patient with Severe Bronchial Asthma. Doctor.Ru. 2020;19(11):38–41. (In Russ). doi: https://doi.org/10.31550/1727-2378-2020-19-11-38-41Hondras MA, Linde K, Jones AP. Manual therapy for asthma. Cochrane Database Syst Rev. 2005;(2):CD001002. doi: https://doi.org/10.1002/14651858.cd001002.pub2Hondras MA, Linde K, Jones AP. Manual therapy for asthma. Cochrane Database Syst Rev. 2005;(2):CD001002. doi: https://doi.org/10.1002/14651858.cd001002.pub2Santino TA, Chaves GSS, Freitas DA, et al. Breathing exercises for adults with asthma. Cochrane Database Syst Rev. 2020;3(3):CD001277. doi: https://doi.org/10.1002/14651858.CD001277.pub4Santino TA, Chaves GSS, Freitas DA, et al. Breathing exercises for adults with asthma. Cochrane Database Syst Rev. 2020;3(3):CD001277. doi: https://doi.org/10.1002/14651858.CD001277.pub4Thomas M. Breathing exercises and asthma. Thorax. 2003;58(8): 649–650. doi: https://doi.org/10.1136/thorax.58.8.649Thomas M. Breathing exercises and asthma. Thorax. 2003;58(8): 649–650. doi: https://doi.org/10.1136/thorax.58.8.649Prem V, Sahoo RC, Adhikari P. Comparison of the effects of Buteyko and pranayama breathing techniques on quality of life in patients with asthma — A randomized controlled trial. Clin Rehabil. 2013;27(2): 133–141. doi: https://doi.org/10.1177/0269215512450521Prem V, Sahoo RC, Adhikari P. Comparison of the effects of Buteyko and pranayama breathing techniques on quality of life in patients with asthma — A randomized controlled trial. Clin Rehabil. 2013;27(2): 133–141. doi: https://doi.org/10.1177/0269215512450521Vagedes K, Kuderer S, Ehmann R, et al. Effect of Buteyko breathing technique on clinical and functional parameters in adult patients with asthma: a randomized, controlled study. Eur J Med Res. 2024;29(1):42. doi: https://doi.org/10.1186/s40001-023-01634-1Vagedes K, Kuderer S, Ehmann R, et al. Effect of Buteyko breathing technique on clinical and functional parameters in adult patients with asthma: a randomized, controlled study. Eur J Med Res. 2024;29(1):42. doi: https://doi.org/10.1186/s40001-023-01634-1Cooper S, Oborne J, Newton S, et al. Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomised controlled trial. Thorax. 2003;58(8):674–679. doi: https://doi.org/10.1136/THORAX.58.8.674Cooper S, Oborne J, Newton S, et al. Effect of two breathing exercises (Buteyko and pranayama) in asthma: a randomised controlled trial. Thorax. 2003;58(8):674–679. doi: https://doi.org/10.1136/THORAX.58.8.674Agarwal D, Gupta PP, Sood S. Assessment for Efficacy of Additional Breathing Exercises Over Improvement in Health Impairment Due to Asthma Assessed using St. George’s Respiratory Questionnaire. Int J Yoga. 2017;10(3):145–151. doi: https://doi.org/10.4103/0973-6131.213472Agarwal D, Gupta PP, Sood S. Assessment for Efficacy of Additional Breathing Exercises Over Improvement in Health Impairment Due to Asthma Assessed using St. George’s Respiratory Questionnaire. Int J Yoga. 2017;10(3):145–151. doi: https://doi.org/10.4103/0973-6131.213472Sankar J, Das RR. Asthma — A Disease of How We Breathe: Role of Breathing Exercises and Pranayam. Indian J Pediatr. 2018;85(10):905–910. doi: https://doi.org/10.1007/s12098-017-2519-6Sankar J, Das RR. Asthma — A Disease of How We Breathe: Role of Breathing Exercises and Pranayam. Indian J Pediatr. 2018;85(10):905–910. doi: https://doi.org/10.1007/s12098-017-2519-6Burgess J, Ekanayake B, Lowe A, et al. Systematic review of the effectiveness of breathing retraining in asthma management. Expert Rev Respir Med. 2011;5(6):789–807. doi: https://doi.org/10.1586/ers.11.69Burgess J, Ekanayake B, Lowe A, et al. Systematic review of the effectiveness of breathing retraining in asthma management. Expert Rev Respir Med. 2011;5(6):789–807. doi: https://doi.org/10.1586/ers.11.69Игнатова Г.Л., Антонов В.Н., Блинова Е.В. и др. Бронхиальная астма у беременных // РМЖ. Мать и дитя. — 2015. — Т. 23. — № 20. — С. 1229–1232.Ignatova GL, Antonov VN, Blinova EV, et al. Bronkhial’naya astma u beremennykh. Russian Journal of Woman and Child Health. 2015;23(20):1229–1232. (In Russ).Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–478. doi: https://doi.org/10.1111/J.1398-9995.2004.00526.XMasoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy. 2004;59(5):469–478. doi: https://doi.org/10.1111/J.1398-9995.2004.00526.XWang H, Li N, Huang H. Asthma in Pregnancy: Pathophysiology, Diagnosis, Whole-Course Management, and Medication Safety. Can Respir J. 2020;2020:9046842. doi: https://doi.org/10.1155/2020/9046842Wang H, Li N, Huang H. Asthma in Pregnancy: Pathophysiology, Diagnosis, Whole-Course Management, and Medication Safety. Can Respir J. 2020;2020:9046842. doi: https://doi.org/10.1155/2020/9046842Alexander S, Dodds L, Armson BA. Perinatal outcomes in women with asthma during pregnancy. Obstet Gynecol. 1998;92(3): 435–440. doi: https://doi.org/10.1016/S0029-7844(98)00191-4Alexander S, Dodds L, Armson BA. Perinatal outcomes in women with asthma during pregnancy. Obstet Gynecol. 1998;92(3): 435–440. doi: https://doi.org/10.1016/S0029-7844(98)00191-4Андреева О.С. Особенности течения и лечения бронхиальной астмы в период беременности: автореф. дис. … канд. мед. наук. — СПб.; 2006. — 21 с.Андреева О.С. Особенности течения и лечения бронхиальной астмы в период беременности: автореф. дис. … канд. мед. наук. — СПб.; 2006. — 21 с. [Andreeva OS. Osobennosti techeniya i lecheniya bronkhial’noi astmy v period beremennosti. [abstract of dissertation]. St. Petersburg; 2026. 21 p. (In Russ).]Vyawahare AP, Gaidhane A, Wandile B. Asthma in Pregnancy: A Critical Review of Impact, Management, and Outcomes. Cureus. 2023;15(12):e50094. doi: https://doi.org/10.7759/cureus.50094Vyawahare AP, Gaidhane A, Wandile B. Asthma in Pregnancy: A Critical Review of Impact, Management, and Outcomes. Cureus. 2023;15(12):e50094. doi: https://doi.org/10.7759/cureus.50094Giles W, Murphy V. Asthma in pregnancy: a review. Obstet Med. 2013;6(2):107–110. doi: https://doi.org/10.1258/OM.2012.120008Giles W, Murphy V. Asthma in pregnancy: a review. Obstet Med. 2013;6(2):107–110. doi: https://doi.org/10.1258/OM.2012.120008Rohrer V, Schmidt-Trucksäss A. Impact of exercise, sport and rehabilitation therapy in asthma and COPD. Ther Umsch. 2014;71(5):295–300. doi: https://doi.org/10.1024/0040-5930/A000516Rohrer V, Schmidt-Trucksäss A. Impact of exercise, sport and rehabilitation therapy in asthma and COPD. Ther Umsch. 2014;71(5):295–300. doi: https://doi.org/10.1024/0040-5930/A000516Thomas M. Allergic rhinitis: evidence for impact on asthma. BMC Pulm Med. 2006;6 Suppl 1(Suppl 1):S4. doi: https://doi.org/10.1186/1471-2466-6-S1-S4Thomas M. Allergic rhinitis: evidence for impact on asthma. BMC Pulm Med. 2006;6 Suppl 1(Suppl 1):S4. doi: https://doi.org/10.1186/1471-2466-6-S1-S4Wise SK, Lin SY, Toskala E, et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. doi: https://doi.org/10.1002/ALR.22073Wise SK, Lin SY, Toskala E, et al. International Consensus Statement on Allergy and Rhinology: Allergic Rhinitis. Int Forum Allergy Rhinol. 2018;8(2):108–352. doi: https://doi.org/10.1002/ALR.22073Vignola AM, Chanez P, Godard P, Bousquet J. Relationships between rhinitis and asthma. Allergy. 1998;53(9):833–839. doi: https://doi.org/10.1111/J.1398-9995.1998.TB03988.XVignola AM, Chanez P, Godard P, Bousquet J. Relationships between rhinitis and asthma. Allergy. 1998;53(9):833–839. doi: https://doi.org/10.1111/J.1398-9995.1998.TB03988.XJacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–948. doi: https://doi.org/10.1111/J.1398-9995.2007.01451.XJacobsen L, Niggemann B, Dreborg S, et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62(8):943–948. doi: https://doi.org/10.1111/J.1398-9995.2007.01451.XArshad H, Lack G, Durham SR, et al. Prevention Is Better than Cure: Impact of Allergen Immunotherapy on the Progression of Airway Disease. J Allergy Clinl Immunol Pract. 2024;12(1):45–56. doi: https://doi.org/10.1016/J.JAIP.2023.10.013Arshad H, Lack G, Durham SR, et al. Prevention Is Better than Cure: Impact of Allergen Immunotherapy on the Progression of Airway Disease. J Allergy Clinl Immunol Pract. 2024;12(1):45–56. doi: https://doi.org/10.1016/J.JAIP.2023.10.013Методические указания МУ 3.3.1.1095-02. Медицинские противопоказания к проведению профилактических прививок препаратами национального календаря прививок. Доступно по: https://legalacts.ru/doc/mu-3311095-02-331-vaktsinoprofilaktika-meditsinskieprotivopokazanija-k/?ysclid=mcdjwgyift119412374. Ссылка активна на 26.06.2025.Methodological instructions МУ 3.3.1.1095-02. Meditsinskie protivopokazaniya k provedeniyu profilakticheskikh privivok preparatami natsional’nogo kalendarya privivok. (In Russ). Доступно по: https://legalacts.ru/doc/mu-3311095-02-331-vaktsinoprofilaktika-meditsinskieprotivopokazanija-k/?ysclid=mcdjwgyift119412374. Ссылка активна на 26.06.2025.Nilsson L, Brockow K, Alm J, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017;28(7):628–640. doi: https://doi.org/10.1111/PAI.12762Nilsson L, Brockow K, Alm J, et al. Vaccination and allergy: EAACI position paper, practical aspects. Pediatr Allergy Immunol. 2017;28(7):628–640. doi: https://doi.org/10.1111/PAI.12762Gao YD, Xepapadaki P, Cui YW, et al. Effect of Haemophilus influenzae, Streptococcus pneumoniae and influenza vaccinations on infections, immune response and asthma control in preschool children with asthma. Allergy. 2023;78(6):1473–1488. doi: https://doi.org/10.1111/ALL.15551Gao YD, Xepapadaki P, Cui YW, et al. Effect of Haemophilus influenzae, Streptococcus pneumoniae and influenza vaccinations on infections, immune response and asthma control in preschool children with asthma. Allergy. 2023;78(6):1473–1488. doi: https://doi.org/10.1111/ALL.15551Zaidi SR, Blakey JD. Why are people with asthma susceptible to pneumonia? A review of factors related to upper airway bacteria. Respirology. 2019;24(5):423–430. doi: https://doi.org/10.1111/RESP.13528Zaidi SR, Blakey JD. Why are people with asthma susceptible to pneumonia? A review of factors related to upper airway bacteria. Respirology. 2019;24(5):423–430. doi: https://doi.org/10.1111/RESP.13528Вакцинопрофилактика пневмококковой инфекции у детей и взрослых: методические рекомендации / под ред. А.А. Баранова, Л.С. Намазовой-Барановой, Н.И. Брико; Союз педиатров России. — М.: ПедиатрЪ; 2023. — 92 с.Vaktsinoprofilaktika pnevmokokkovoi infektsii u detei i vzroslykh: Methodological recommendations. Baranov AA, Namazova-Baranova LS, Briko NI, eds.; Union of Pediatricians of Russia. Moscow: Pediatr; 2023. 92 p. (In Russ).Pneumococcal vaccines WHO position paper — 2012. Wkly Epidemiol Rec. 2012;87(14):129–144.Pneumococcal vaccines WHO position paper — 2012. Wkly Epidemiol Rec. 2012;87(14):129–144.Чучалин А.Г., Биличенко Т.Н., Осипова Г.Л. и др. Вакцинопрофилактика болезней органов дыхания в рамках первичной медико-санитарной помощи населению // Пульмонология. Приложение. — 2015. — № 2. — С. 3–19.Chuchalin AG, Bilichenko TN, Osipova GL, et al. Vaktsinoprofilaktika boleznei organov dykhaniya v ramkakh pervichnoi mediko-sanitarnoi pomoshchi naseleniyu. Pul’monologiya. Prilozhenie. 2015;(2):3–19. (In Russ).Capili CR, Hettinger A, Rigelman-Hedberg N, et al. Increased risk of pertussis in patients with asthma. J Allergy Clin Immunol. 2012;129(4):957–963. doi: https://doi.org/10.1016/J.JACI.2011.11.020Capili CR, Hettinger A, Rigelman-Hedberg N, et al. Increased risk of pertussis in patients with asthma. J Allergy Clin Immunol. 2012;129(4):957–963. doi: https://doi.org/10.1016/J.JACI.2011.11.020Buck PO, Meyers JL, Gordon LD, et al. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017;145(10):2109–2121. doi: https://doi.org/10.1017/S0950268817000887Buck PO, Meyers JL, Gordon LD, et al. Economic burden of diagnosed pertussis among individuals with asthma or chronic obstructive pulmonary disease in the USA: an analysis of administrative claims. Epidemiol Infect. 2017;145(10):2109–2121. doi: https://doi.org/10.1017/S0950268817000887Harju TH, Leinonen M, Nokso-Koivisto J, et al. Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma. Thorax. 2006;61(7):579–584. doi: https://doi.org/10.1136/THX.2005.056291Harju TH, Leinonen M, Nokso-Koivisto J, et al. Pathogenic bacteria and viruses in induced sputum or pharyngeal secretions of adults with stable asthma. Thorax. 2006;61(7):579–584. doi: https://doi.org/10.1136/THX.2005.056291Mbayei SA, Faulkner A, Miner C, et al. Severe Pertussis Infections in the United States, 2011–2015. Clin Infect Dis. 2019;69(2):218–226. doi: https://doi.org/10.1093/CID/CIY889Mbayei SA, Faulkner A, Miner C, et al. Severe Pertussis Infections in the United States, 2011–2015. Clin Infect Dis. 2019;69(2):218–226. doi: https://doi.org/10.1093/CID/CIY889Bateman ED, Bousquet J, Keech ML, et al. The correlation between asthma control and health status: the GOAL study. Eur Respir J. 2007;29(1):59–63. doi: https://doi.org/10.1183/09031936.00128505Bateman ED, Bousquet J, Keech ML, et al. The correlation between asthma control and health status: the GOAL study. Eur Respir J. 2007;29(1):59–63. doi: https://doi.org/10.1183/09031936.00128505Sont JK. How do we monitor asthma control? Allergy. 1999;54 Suppl 49:68–73. doi: https://doi.org/10.1111/J.1398-9995.1999.TB04391.XSont JK. How do we monitor asthma control? Allergy. 1999;54 Suppl 49:68–73. doi: https://doi.org/10.1111/J.1398-9995.1999.TB04391.XSchatz M, Rachelefsky G, Krishnan JA. Follow-up after acute asthma episodes: what improves future outcomes? Proc Am Thorac Soc. 2009;6(4):386–393. doi: https://doi.org/10.1513/PATS.P09ST6Schatz M, Rachelefsky G, Krishnan JA. Follow-up after acute asthma episodes: what improves future outcomes? Proc Am Thorac Soc. 2009;6(4):386–393. doi: https://doi.org/10.1513/PATS.P09ST6Ducharme FM, Bhogal SK. The role of written action plans in childhood asthma. Curr Opin Allergy Clin Immunol. 2008;8(2): 177–188. doi: https://doi.org/10.1097/ACI.0B013E3282F7CD58Ducharme FM, Bhogal SK. The role of written action plans in childhood asthma. Curr Opin Allergy Clin Immunol. 2008;8(2): 177–188. doi: https://doi.org/10.1097/ACI.0B013E3282F7CD58Gibson PG, Powell H. Written action plans for asthma: an evidencebased review of the key components. Thorax. 2004;59(2):94–99. doi: https://doi.org/10.1136/THORAX.2003.011858Gibson PG, Powell H. Written action plans for asthma: an evidencebased review of the key components. Thorax. 2004;59(2):94–99. doi: https://doi.org/10.1136/THORAX.2003.011858Al-Awaisheh RI, Alsayed AR, Basheti IA. Assessing the Pharmacist’s Role in Counseling Asthmatic Adults Using the Correct Inhaler Technique and Its Effect on Asthma Control, Adherence, and Quality of Life. Patient Prefer Adherence. 2023;17:961–972. doi: https://doi.org/10.2147/PPA.S395258Al-Awaisheh RI, Alsayed AR, Basheti IA. Assessing the Pharmacist’s Role in Counseling Asthmatic Adults Using the Correct Inhaler Technique and Its Effect on Asthma Control, Adherence, and Quality of Life. Patient Prefer Adherence. 2023;17:961–972. doi: https://doi.org/10.2147/PPA.S395258Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938. doi: https://doi.org/10.1016/J.RMED.2011.01.005Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced disease control. Respir Med. 2011;105(6):930–938. doi: https://doi.org/10.1016/J.RMED.2011.01.005Rodrigues Pacheco D, Vieira C, Freitas I, et al. Optimization of Inhalation Technique Knowledge in the Pharmacies of Matosinhos Municipality, Portugal: An Intervention Project. Cureus. 2023;15(12):e50655. doi: https://doi.org/10.7759/cureus.50655Rodrigues Pacheco D, Vieira C, Freitas I, et al. Optimization of Inhalation Technique Knowledge in the Pharmacies of Matosinhos Municipality, Portugal: An Intervention Project. Cureus. 2023;15(12):e50655. doi: https://doi.org/10.7759/cureus.50655Alotaibi MM, Hughes L, Ford WR. Assessing Inhaler Techniques of Asthma Patients Using Aerosol Inhalation Monitors (AIM): A Cross Sectional Study. Healthcare (Basel). 2023;11(8):1125. doi: https://doi.org/10.3390/healthcare11081125Alotaibi MM, Hughes L, Ford WR. Assessing Inhaler Techniques of Asthma Patients Using Aerosol Inhalation Monitors (AIM): A Cross Sectional Study. Healthcare (Basel). 2023;11(8):1125. doi: https://doi.org/10.3390/healthcare11081125Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J Allergy Clin Immunol. 2007;119(6):1537–1538. doi: https://doi.org/10.1016/J.JACI.2007.02.037Basheti IA, Reddel HK, Armour CL, Bosnic-Anticevich SZ. Improved asthma outcomes with a simple inhaler technique intervention by community pharmacists. J Allergy Clin Immunol. 2007;119(6):1537–1538. doi: https://doi.org/10.1016/J.JACI.2007.02.037Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of Inhaled Corticosteroids on Growth in Children with Asthma: Systematic Review and Meta-Analysis. PloS One. 2015;10(7):e0133428. doi: https://doi.org/10.1371/JOURNAL.PONE.0133428Loke YK, Blanco P, Thavarajah M, Wilson AM. Impact of Inhaled Corticosteroids on Growth in Children with Asthma: Systematic Review and Meta-Analysis. PloS One. 2015;10(7):e0133428. doi: https://doi.org/10.1371/JOURNAL.PONE.0133428Brown PH, Blundell G, Greening AP, Crompton GK. Hypothalamopituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med. 1991;85(6):501–510. doi: https://doi.org/10.1016/S0954-6111(06)80268-4Brown PH, Blundell G, Greening AP, Crompton GK. Hypothalamopituitary-adrenal axis suppression in asthmatics inhaling high dose corticosteroids. Respir Med. 1991;85(6):501–510. doi: https://doi.org/10.1016/S0954-6111(06)80268-4Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117(3):549–556. doi: https://doi.org/10.1016/J.JACI.2006.01.011Schatz M, Sorkness CA, Li JT, et al. Asthma Control Test: reliability, validity, and responsiveness in patients not previously followed by asthma specialists. J Allergy Clin Immunol. 2006;117(3):549–556. doi: https://doi.org/10.1016/J.JACI.2006.01.011Schatz M, Mosen DM, Kosinski M, et al. Validity of the Asthma Control Test completed at home. Am J Manag Care. 2007;13(12):661–667.Schatz M, Mosen DM, Kosinski M, et al. Validity of the Asthma Control Test completed at home. Am J Manag Care. 2007;13(12):661–667.Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol. 2007;119(4):817–825. doi: https://doi.org/10.1016/J.JACI.2006.12.662Liu AH, Zeiger R, Sorkness C, et al. Development and cross-sectional validation of the Childhood Asthma Control Test. J Allergy Clin Immunol. 2007;119(4):817–825. doi: https://doi.org/10.1016/J.JACI.2006.12.662Juniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi: https://doi.org/10.1034/j.1399-3003.1999.14d29.xJuniper EF, O’Byrne PM, Guyatt GH, et al. Development and validation of a questionnaire to measure asthma control. Eur Respir J. 1999;14(4):902–907. doi: https://doi.org/10.1034/j.1399-3003.1999.14d29.xChipps B, Zeiger RS, Murphy K, et al. Longitudinal validation of the Test for Respiratory and Asthma Control in Kids in pediatric practices. Pediatrics. 2011;127(3):737–747. doi: https://doi.org/10.1542/peds.2010-1465Chipps B, Zeiger RS, Murphy K, et al. Longitudinal validation of the Test for Respiratory and Asthma Control in Kids in pediatric practices. Pediatrics. 2011;127(3):737–747. doi: https://doi.org/10.1542/peds.2010-1465Haselkorn T, Fish JE, Zeiger RS, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2009;124:895–902.e1–4. doi: https://doi.org/10.1016/j.jaci.2009.07.035Haselkorn T, Fish JE, Zeiger RS, et al. Consistently very poorly controlled asthma, as defined by the impairment domain of the Expert Panel Report 3 guidelines, increases risk for future severe asthma exacerbations in The Epidemiology and Natural History of Asthma: Outcomes and Treatment Regimens (TENOR) study. J Allergy Clin Immunol. 2009;124:895–902.e1–4. doi: https://doi.org/10.1016/j.jaci.2009.07.035Murray CS, Poletti G, Kebadze T, et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax. 2006;61(5):376–382. doi: https://doi.org/10.1136/thx.2005.042523Murray CS, Poletti G, Kebadze T, et al. Study of modifiable risk factors for asthma exacerbations: virus infection and allergen exposure increase the risk of asthma hospital admissions in children. Thorax. 2006;61(5):376–382. doi: https://doi.org/10.1136/thx.2005.042523Mazenq J, Dubus JC, Gaudart J, et al. City housing atmospheric pollutant impact on emergency visit for asthma: A classification and regression tree approach. Respir Med. 2017;132:1–8. doi: https://doi.org/10.1016/j.rmed.2017.09.004Mazenq J, Dubus JC, Gaudart J, et al. City housing atmospheric pollutant impact on emergency visit for asthma: A classification and regression tree approach. Respir Med. 2017;132:1–8. doi: https://doi.org/10.1016/j.rmed.2017.09.004Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343.Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the global lung function 2012 equations. Eur Respir J. 2012;40(6):1324–1343.Hagan JB, Samant SA, Volcheck GW, et al. The risk of asthma exacerbation after reducing inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. Allergy. 2014;69(4):510–516. doi: https://doi.org/10.1111/ALL.12368Hagan JB, Samant SA, Volcheck GW, et al. The risk of asthma exacerbation after reducing inhaled corticosteroids: a systematic review and meta-analysis of randomized controlled trials. Allergy. 2014;69(4):510–516. doi: https://doi.org/10.1111/ALL.12368Терехова Е.П., Себекина О.В., Ненашева Н.М., Терехов Д.В. Правильный выбор ингаляционного устройства как фактор повышения приверженности назначенной терапии у пациента с бронхиальной астмой // Практическая аллергология. — 2021. — № 2. — С. 54–65. — doi: https://doi.org/10.46393/2712-9667_2021_2_54_65Terekhova EP, Sebekina OV, Nenasheva NM, Terekhov DV. The right choice of inhalation device as a factor of increasing adherence to the prescribed therapy in a patient with bronchial asthma. Practical Allergology. 2021;(2);54–65. (In Russ). doi: https://doi.org/10.46393/2712-9667_2021_2_54_65Ненашева Н.М. Бронхиальная астма. Современный взгляд на проблему. — М.: ГЭОТАР-Медиа; 2018. — 304 с.Nenasheva NM. Bronkhial’naya astma. Sovremennyi vzglyad na problemu. Moscow: GEOTAR-Media; 2018. 304 p. (In Russ).

The authors declare that there are no conflicts of interest present.